This implementation guide has been developed to assist in the following activities associated with the collection and compilation of data in a clinical trial.
本实施指南旨在协助与临床试验中数据收集和汇编相关的以下活动。

The Clinical Data Acquisition Standards Harmonization (CDASH) Model, the CDASH Implementation Guide (CDASHIG), and the CDASHIG Metadata Table define basic standards for the collection of clinical trial data and how to implement the standard for specific case report forms. CDASH establishes a standard way to collect data in a similar way across studies and sponsors, so that data collection formats and structures provide clear traceability of submission data into the Study Data Tabulation Model (SDTM), delivering more transparency to regulators and others who conduct data review. The CDASH standard is part of the Clinical Data Interchange Standards Consortium (CDISC) Technical Road Map, which is designed to realize the vision of a set of beginning-to-end harmonized standards for the representation of data from clinical studies throughout the data lifecycle. The CDASH standard directly supports the production of clinical data collection instruments. Through this support, the standard also contributes to:
临床数据采集标准协调（CDASH）模型、CDASH 实施指南（CDASHIG）和 CDASHIG 元数据表定义了临床试验数据收集的基本标准以及如何针对特定病例报告表实施该标准。CDASH 建立了一种在研究和赞助商之间以类似方式收集数据的标准方法，从而使数据收集格式和结构提供清晰的提交数据追溯到研究数据汇总模型（SDTM），为监管机构和其他进行数据审查的人员提供更多透明度。CDASH 标准是临床数据交换标准联盟（CDISC）技术路线图的一部分，旨在实现一套从头到尾协调一致的标准，以表示临床研究数据在整个数据生命周期中的表现。CDASH 标准直接支持临床数据收集工具的生产。通过这种支持，该标准还为以下方面做出贡献：

• Efficient development of research protocols
  高效开发研究方案
• Streamlined processes within medical research
  医疗研究中的简化流程
• Development of a corporate library of standardized CRFs
  标准化 CRF 的企业图书馆开发
• Use of metadata repositories
  使用元数据仓库
• Reporting and regulatory submission
  报告和监管提交
• Data warehouse population
  数据仓库填充
• Data archiving  数据归档
• Post-marketing studies/safety surveillance
  上市后研究/安全监测

For more information, click on the following link: http://www.cdisc.org/strategies-and-goals.
有关更多信息，请点击以下链接：http://www.cdisc.org/strategies-and-goals。

There is growing recognition around the globe that industry standards promote data interchange, which is essential to effective partnering and information exchange between and among clinicians and researchers. Clinical care can more easily reap benefits through medical research findings, and more clinicians will be interested in conducting research if the research process can be integrated into their clinical care workflow. CDISC encourages the adoption of its global standards for clinical research, which should continue to be harmonized with healthcare standards, to provide a means for interoperability among healthcare and research systems such that medical research can support informed healthcare decisions and improve patient safety.
全球越来越认识到行业标准促进数据交换，这对临床医生和研究人员之间的有效合作和信息交流至关重要。临床护理可以更容易地从医学研究成果中获益，如果研究过程能够融入他们的临床护理工作流程，更多的临床医生将会对进行研究感兴趣。CDISC 鼓励采用其全球临床研究标准，这些标准应继续与医疗保健标准保持一致，以提供医疗保健和研究系统之间的互操作性，从而使医学研究能够支持知情的医疗决策并提高患者安全。

This document is intended to be used by persons involved in the planning, collection, management, and analysis of clinical trials and clinical data, including Clinical Investigators, Medical Monitors, Clinical Research Associates (Monitors), Clinical Research Study Coordinators, Clinical Data Standards Subject Matter Experts (SMEs), Clinical Data Managers, Clinical Data and Statistical Programmers, Biostatisticians, Drug Safety, Case Report Form (CRF) Designers, and other functions tasked with the responsibility to collect, clean, and ensure the integrity of clinical trial data.
本文件旨在供参与临床试验和临床数据的规划、收集、管理和分析的人员使用，包括临床研究者、医学监测员、临床研究助理（监测员）、临床研究协调员、临床数据标准主题专家（SME）、临床数据经理、临床数据和统计程序员、生物统计学家、药物安全、病例报告表（CRF）设计师以及其他负责收集、清理和确保临床试验数据完整性的职能。

This document has been organized into the following sections:
本文件已组织为以下几个部分：

• Section 1, Orientation 第一部分，导向
• Section 2, How to Use the CDASH Standard
  第 2 节，如何使用 CDASH 标准
• Section 3, General Assumptions for Implementing CDASH
  第 3 节，实施 CDASH 的一般假设
• Section 4, Best Practice Recommendations
  第 4 节，最佳实践建议
• Section 5, Conformance Rules
  第 5 节，符合性规则
• Section 6, Other Information
  第六节，其他信息
• Section 7, CDASH Special-Purpose Domains
  第 7 节，CDASH 特殊用途领域
• Section 8, General Observation Classes
  第 8 节，一般观察类
• Appendices 附录

• Paper CRFs vs. Electronic CRFs: The term "CRF" used throughout this document refers to both paper and electronic formats, unless otherwise specified.
  纸质 CRF 与电子 CRF：本文档中使用的“CRF”一词指纸质和电子格式，除非另有说明。
• Fields vs. Variables: Data collection "fields" refers to terms that are commonly on the CRF. Data collection "variables" refers to what is in a clinical database.
  字段与变量：数据收集“字段”是指在 CRF 上常见的术语。数据收集“变量”是指临床数据库中的内容。
• Study Treatment: The phrase "study treatment" has been used instead of investigational/medicinal product, study drug, test article, medical device, etc., in order to include all types of study designs and products.
  研究治疗：为了涵盖所有类型的研究设计和产品，使用“研究治疗”这个短语来代替研究性/药物产品、研究药物、测试产品、医疗设备等。
• Mechanisms for Data Collection: Different data collection mechanisms can be used to control how data are collected (e.g., tick boxes, check boxes, radio buttons, drop-down lists, etc.). For the purposes of this document, these terms will be used interchangeably.
  数据收集机制：可以使用不同的数据收集机制来控制数据的收集方式（例如，勾选框、复选框、单选按钮、下拉列表等）。在本文件中，这些术语将交替使用。

CDASH is composed of the CDASH Model and the CDASH Implementation Guide (CDASHIG), with its associated CDASHIG Metadata Table. A domain is a collection of data points related by a common topic, such as adverse events or demographics. CDASHIG domains are aligned with SDTMIG domains for beginning-to-end traceability.
CDASH 由 CDASH 模型和 CDASH 实施指南（CDASHIG）组成，并附有 CDASHIG 元数据表。领域是与共同主题相关的数据点集合，例如不良事件或人口统计。CDASHIG 领域与 SDTMIG 领域对齐，以实现从头到尾的可追溯性。

CDASH Model CDASH 模型

The CDASH Model v1.0 provides a general framework for creating fields to collect information on CRFs and includes the model metadata, which shows the standard variables in the model. The CDASHIG provides information on the implementation of the CDASH Model and includes the CDASHIG Metadata Table, which details additional specifications for data collection variables within each domain.
CDASH 模型 v1.0 提供了一个通用框架，用于创建字段以收集 CRF 上的信息，并包括模型元数据，显示模型中的标准变量。CDASHIG 提供了关于 CDASH 模型实施的信息，并包括 CDASHIG 元数据表，详细说明了每个领域内数据收集变量的附加规范。

The CDASH Model v1.0 provides root naming conventions for CDASHIG variables that are intended to facilitate mapping to the SDTMIG variables. The variables defined in the CDASH model follow the same "--XXXX" naming convention as the SDTM model. The two dashes are replaced by the domain code when applied to create the CDASHIG variable. For example, --DOSFRQ is the CDASH Model variable name to for Dosing Frequency per Interval in the Interventions Class. When a domain abbreviation is applied (e.g., "CM"), CMDOSFRQ is the CDASHIG variable for the frequency of the concomitant medication use. The CDASH Model includes metadata for variables used in each of the SDTM general observation classes, Timing variables, Identifier variables, variables for Special Purpose domains, and domain-specific variables. See Section 3.5 for specific information on the CDASH Model content.
CDASH 模型 v1.0 提供了 CDASHIG 变量的根命名约定，旨在促进与 SDTMIG 变量的映射。CDASH 模型中定义的变量遵循与 SDTM 模型相同的“--XXXX”命名约定。当应用于创建 CDASHIG 变量时，两个破折号会被领域代码替换。例如，--DOSFRQ 是干预类中每个间隔的给药频率的 CDASH 模型变量名称。当应用领域缩写时（例如，“CM”），CMDOSFRQ 是伴随用药频率的 CDASHIG 变量。CDASH 模型包括用于每个 SDTM 一般观察类、时间变量、标识符变量、特殊目的领域变量和领域特定变量的元数据。有关 CDASH 模型内容的具体信息，请参见第 3.5 节。

CDASHIG

The CDASHIG provides general information on the implementation of CDASH standards. The CDASH standards include the CDASH Model and the CDASHIG, which includes the supporting CDASHIG Metadata Table. The informative content of the CDASHIG and the normative content metadata table comprise the CDASHIG and must be referenced together.
CDASHIG 提供了关于 CDASH 标准实施的一般信息。CDASH 标准包括 CDASH 模型和 CDASHIG，其中包含支持的 CDASHIG 元数据表。CDASHIG 的说明性内容和规范性内容元数据表构成了 CDASHIG，必须一起引用。

CDASHIG Metadata Table CDASHIG 元数据表

The CDASHIG Metadata Table includes only those variables commonly implemented by a significant number of the organizations/companies that provided information/examples (e.g., Medical History, Adverse Events). Implementers can add appropriate variables to their CDASHIG domain using the associated General Observation class within the CDASH Model. The CDASHIG Domain Metadata illustrates the use of Question Text and Prompts employed by many sponsors. Implementers should reference the CDASH Model to see all available options for Question Text and Prompt for parameters and verb tenses that may be substituted.
CDASHIG 元数据表仅包括由提供信息/示例的许多组织/公司普遍实施的变量（例如，病史、不良事件）。实施者可以使用 CDASH 模型中的相关一般观察类将适当的变量添加到他们的 CDASHIG 领域。CDASHIG 领域元数据展示了许多赞助商使用的问题文本和提示。实施者应参考 CDASH 模型，以查看可用于参数和可能替代的动词时态的问题文本和提示的所有可用选项。

The CDASHIG Metadata Table attributes provide building blocks for the development of a case report form and the underlying database or other data collection structure.
CDASHIG 元数据表属性为案例报告表及其基础数据库或其他数据收集结构的开发提供了构建模块。

The key steps to developing CRFs using CDASH are as follows:
使用 CDASH 开发 CRF 的关键步骤如下：

1. Each organization may maintain a corporate library of standardized CRFs. Determine the requirements for data domains from these (if applicable) or the protocol data collection requirements for the study.
   每个组织可以维护一个标准化 CRF 的企业库。根据这些（如适用）确定数据领域的要求或研究的协议数据收集要求。
2. Review the domains published in CDASHIG to determine which of the data collection domains and fields are already specified in the published domains.
   审查 CDASHIG 中发布的领域，以确定哪些数据收集领域和字段已在发布的领域中指定。
3. As much as possible, the standard domains should be used to collect data in a manner that will be effective for data collection. Develop the data collection tools using these published, standard domains first.
   尽可能使用标准领域以有效的方式收集数据。首先使用这些已发布的标准领域开发数据收集工具。

4. Using the root variables and other CDASH metadata in the CDASH Model, add any additional variables that are needed to meet the requirements of data collection. Follow CDISC Variable-Naming Fragments (see the CDASHIG Glossary and Abbreviations) conventions, and CDASH root variable naming conventions where they exist (e.g., --DAT for dates, --TIM for times, --YN for prompts as described in the CDASH Model).
   使用 CDASH 模型中的根变量和其他 CDASH 元数据，添加满足数据收集要求所需的任何附加变量。遵循 CDISC 变量命名片段（参见 CDASHIG 术语表和缩略语）约定，以及存在的 CDASH 根变量命名约定（例如，--DAT 用于日期，--TIM 用于时间，--YN 用于 CDASH 模型中描述的提示）。

   Example: Replace "--" with the two-character domain code that matches the other variables in the same domain. For example, to add the --LOC variable to a Medical History CRF, the domain code is "MH", so the variable would become "MHLOC" in that domain.
   示例：将“--”替换为与同一领域中其他变量匹配的两字符域代码。例如，要将--LOC 变量添加到医疗历史 CRF 中，域代码为“MH”，因此该变量在该领域中将变为“MHLOC”。

5. The Question Text and Prompt columns in the CDASH Model provide different variations in the recommended text for asking the question on a CRF. For each question, the sponsor may elect to either use the Question Text or the Prompt on the CRF. Some text is presented using brackets [ ], parentheses ( ), and/or incorporating forward slashes. These different formats are used to indicate how the Question Text or Prompt may be modified by the sponsor.
   CDASH 模型中的问题文本和提示列提供了在 CRF 上询问问题的推荐文本的不同变体。对于每个问题，赞助商可以选择在 CRF 上使用问题文本或提示。一些文本使用方括号[ ]、圆括号( )和/或包含斜杠。这些不同的格式用于指示赞助商如何修改问题文本或提示。

   1. The text inside the brackets provides an option on the tense of the question, or text that can be replaced with protocol specific verbiage.
      括号内的文本提供了问题时态的选项，或可以用特定协议的术语替换的文本。

   2. The text inside the parentheses provides options (e.g., singular/plural) or text that may be eliminated.
      括号内的文本提供选项（例如，单数/复数）或可能被省略的文本。

   3. Text separated with a forward slash provides optional words which the sponsor may choose.
      文本中用斜杠分隔的内容提供了赞助商可以选择的可选词。

      Example: The CDASH variable, --PERF, from the CDASH Model has the following Question Text and Prompt.
      示例：CDASH 模型中的 CDASH 变量--PERF 具有以下问题文本和提示。

      Question Text: 问题文本：

      [Were any/Was the] [--TEST/ topic] [measurement(s)/test(s)/examination(s)/specimen(s)/sample(s)] [performed/collected]?
      [是否进行了] [--测试/主题] [测量/测试/检查/样本] [？]

      Prompt: 提示：

      [--TEST/Topic] [Measurement(s)/Test(s)/Examination(s)/Specimen(s)/Sample(s)] [Performed/Collected]?
      [--测试/主题] [测量/测试/检查/标本/样本] [执行/收集]?

      The sponsor wants to add a question to a CRF that asks whether a lab specimen was collected using a yes, no response.
      赞助商希望在 CRF 中添加一个问题，询问实验室样本是否已收集，回答为“是”或“否”。

      a) The sponsor selects the CDASH variable --PERF and adds the appropriate domain code. LBPERF
      赞助商选择 CDASH 变量--PERF 并添加适当的领域代码。LBPERF

      b) Use either the Prompt or the full Question Text on the CRF.
      b) 在 CRF 上使用提示或完整问题文本。

      Question Text: Was the laboratory specimen collected?
      实验室样本是否已收集？

      1. In the first set of brackets, the text option "Was the" is selected as the study required only one lab test to be performed. [Were any/Was the]
         在第一个括号中，文本选项“Was the”被选中，因为研究只需要进行一次实验室测试。[Were any/Was the]
      2. In the second set of brackets, the text used is "laboratory" which is the topic of interest. [--TEST/Topic (laboratory)]
         在第二组括号中，使用的文本是“实验室”，这是感兴趣的主题。[--TEST/Topic (实验室)]
      3. In the third set of brackets, the text option "specimen" without the optional "s" is selected. [measurement(s)/test(s)/examination(s)/specimen(s)/sample(s)]
         在第三组括号中，选择了不带可选“s”的文本选项“specimen”。[measurement(s)/test(s)/examination(s)/specimen(s)/sample(s)]
      4. In the fourth set of brackets, the text option "collected" is selected. [performed/collected]
         在第四组括号中，选择了文本选项“收集”。 [执行/收集]

      Prompt: Laboratory Specimen Collected
      实验室样本已收集

      1. In the first set of brackets, the text used is the topic of interest (i.e., laboratory). [--TEST/Topic (Laboratory)]
         在第一个括号中，使用的文本是感兴趣的主题（即，实验室）。[--测试/主题（实验室）]
      2. In the second set of brackets, the text option "specimen" without the optional "s" is selected. [Measurement(s)/Test(s)/Examination(s)/Specimen(s)/Sample(s)]
         在第二组括号中，选择了没有可选“s”的文本选项“specimen”。[测量/测试/检查/标本/样本]
      3. In the third set of brackets, the text option "collected" is selected. [Performed/Collected]
         在第三组括号中，选择了文本选项“收集”。[执行/收集]
6. Create custom domains based on one of the General Observation Classes in the CDASH Model.
   根据 CDASH 模型中的一般观察类别创建自定义域。

The CDASHIG Metadata Table attributes provide building blocks for the development of a case report form and the underlying database or other data collection structure.
CDASHIG 元数据表属性为案例报告表及其基础数据库或其他数据收集结构的开发提供了构建模块。

1. The Study Data Tabulation Model (SDTM) and the SDTM Implementation Guide (SDTMIG) provide a standard for the submission of data. CDASH is earlier in the data flow and defines a basic set of data collection fields that are expected to be present on the majority of CRFs. SDTM and CDASH are clearly related. The use of CDASH data collection fields and variables is intended to facilitate mapping to the SDTM structure. When the data are identical between the two standards, the SDTMIG variable names are presented in the CDASHIG Metadata Table and should be used to collect the data. In cases where the data are not identical or do not exist in the SDTMIG, CDASH has created standardized data collection variable names.
   研究数据制表模型（SDTM）和 SDTM 实施指南（SDTMIG）为数据提交提供了标准。CDASH 位于数据流的早期阶段，定义了一组基本的数据收集字段，这些字段预计在大多数 CRF 中会出现。SDTM 和 CDASH 显然是相关的。使用 CDASH 数据收集字段和变量旨在促进与 SDTM 结构的映射。当两个标准之间的数据相同时，SDTMIG 变量名称会在 CDASHIG 元数据表中列出，并应用于数据收集。在数据不相同或在 SDTMIG 中不存在的情况下，CDASH 创建了标准化的数据收集变量名称。
2. The CDASHIG v2.0 content is based on the SDTMIG Version 3.2.
   CDASHIG v2.0 内容基于 SDTMIG 版本 3.2。
3. All SDTMIG "Required" variables have been addressed either directly through data collection or by determining what needs to be collected to derive the SDTMIG variable. In some cases, SDTMIG variable values can be obtained from data sources other than the CRF or are populated during the preparation of the submission datasets (e.g., --SEQ values).
   所有 SDTMIG“必需”变量已通过数据收集直接处理，或通过确定需要收集什么以推导 SDTMIG 变量。在某些情况下，SDTMIG 变量值可以从 CRF 以外的数据源获得，或在准备提交数据集时填充（例如，--SEQ 值）。
4. CDASHIG Domains contain variables that may be used in the creation of the RELREC submission dataset. For example: CDASHIG variable CMAENO: "What [is/was] the identifier for the adverse event(s) related to this (concomitant) [medication/therapy]?" may be used to identify a relationship between records in the CM dataset and records in the AE dataset.
   CDASHIG 领域包含可能用于创建 RELREC 提交数据集的变量。例如：CDASHIG 变量 CMAENO：“与此（伴随）[药物/治疗]相关的不良事件的标识符是什么[是/曾是]？”可用于识别 CM 数据集中的记录与 AE 数据集中的记录之间的关系。
5. The CDASH standard also includes some data collection fields that are not included in the SDTMIG (e.g., "Were any adverse events experienced?" or "Were any (concomitant) [medication(s)/therapy(ies)] taken?"). These data collection fields are intended to assist in the cleaning of data and in confirming that no data are unintentionally missing. To facilitate the use of these types of fields, variable names are provided (e.g., AEYN, CMYN) in the CDASHIG Metadata Table to denote that they are data collection variables, but the SDTMIG Variable Name column is listed as N/A, and the Mapping Instruction column indicates that these CDASHIG variables are not included in the SDTM datasets.
   CDASH 标准还包括一些在 SDTMIG 中未包含的数据收集字段（例如，“是否经历了任何不良事件？”或“是否服用了任何（伴随）[药物/治疗]？”）。这些数据收集字段旨在帮助清理数据，并确认没有数据被无意遗漏。为了方便使用这些类型的字段，CDASHIG 元数据表中提供了变量名称（例如，AEYN，CMYN）以表示它们是数据收集变量，但 SDTMIG 变量名称列标记为 N/A，映射说明列则指示这些 CDASHIG 变量未包含在 SDTM 数据集中。
6. The CDASHIG Findings domain (e.g., Drug Accountability (DA), ECG Test Results (EG) and Vital Signs (VS)) tables are presented in a structure that is similar to the SDTMIG, which is to list the variable names and some examples of the tests. Implementers are expected to include protocol-specific tests in a CRF presentation layout, using the appropriate values from the relevant CDISC Controlled Terminology codelists. For example, VSTEST values are used to name the test on the CRF, and the corresponding test code is determined from the VSTESTCD codelist. Implementers may use synonyms when the xxTEST values are long or not commonly recognized (e.g., ALT in place of Alanine Aminotransferase). Implementers should use the CDASHIG recommendations to identify the types of data to collect while referring to the SDTMIG and CDISC Controlled Terminology for additional metadata, (e.g., labels, data type, controlled terminology).
   CDASHIG 发现领域（例如，药物责任（DA）、心电图测试结果（EG）和生命体征（VS））表格的结构与 SDTMIG 相似，列出了变量名称和一些测试示例。实施者应在 CRF 展示布局中包含特定于方案的测试，使用相关 CDISC 受控术语代码表中的适当值。例如，VSTEST 值用于在 CRF 上命名测试，相应的测试代码由 VSTESTCD 代码表确定。当 xxTEST 值较长或不常被认可时，实施者可以使用同义词（例如，用 ALT 代替丙氨酸氨基转移酶）。实施者应使用 CDASHIG 建议来识别要收集的数据类型，同时参考 SDTMIG 和 CDISC 受控术语以获取附加元数据（例如，标签、数据类型、受控术语）。
7. The CDASH standard has intentionally not reproduced other sections of the SDTM standard and implementers are asked to refer to the SDTM Model and SDTMIG on the CDISC website for additional information (http://www.cdisc.org/sdtm).
   CDASH 标准故意没有重现 SDTM 标准的其他部分，实施者被要求参考 CDISC 网站上的 SDTM 模型和 SDTMIG 以获取更多信息（http://www.cdisc.org/sdtm）。
8. The CDASHIG data collection fields included in the CDASHIG Metadata Table are the most commonly used and should be easily identified by most implementers. Additional data collection fields may be necessary to capture therapeutic area (TA) specific data points as well as other data specified in the clinical study protocol or for local regulatory requirements. Reference the CDASH Model and CDISC Therapeutic Area User Guides for additional information.
   CDASHIG 元数据表中包含的 CDASHIG 数据收集字段是最常用的，应该能被大多数实施者轻松识别。可能需要额外的数据收集字段来捕获特定于治疗领域（TA）的数据点，以及临床研究方案中规定的其他数据或当地监管要求。有关更多信息，请参考 CDASH 模型和 CDISC 治疗领域用户指南。
9. Use the CDASH recommendations to develop company standards, taking into consideration the stage of clinical development and the individual therapeutic area requirements. To gain the greatest benefit from using the CDASH standard, CRFs should not be developed on a trial-by-trial basis within the implementer organization, but rather be brought into a study from a library of approved CRFs based on the CDASH Model and Implementation Guide, whenever practicable.
   使用 CDASH 建议制定公司标准，考虑临床开发阶段和各个治疗领域的要求。为了最大限度地利用 CDASH 标准，CRF 不应在实施组织内逐个试验开发，而应尽可能从基于 CDASH 模型和实施指南的已批准 CRF 库中引入到研究中。
10. The CDASHIG is divided into sections of similar types of data and the CDASHIG Metadata Table is arranged in alphabetical order (by domain abbreviation) within their respective general observation class. CRF layout was not within the original scope of the CDASH project; however, to assist with standardization of CRF layout, data collection fields are presented within the CDASHIG Metadata Table in a logical order, and annotated example CRFs have been provided (if available). In addition, implementers are referred to Best Practice for Creating Data Collection Instruments (Best Practice Recommendations), for a discussion on best practices for ordering fields on a case report form.
    CDASHIG 被分为相似类型数据的部分，CDASHIG 元数据表按字母顺序（按领域缩写）排列在各自的一般观察类别内。CRF 布局不在 CDASH 项目的原始范围内；然而，为了帮助标准化 CRF 布局，数据收集字段在 CDASHIG 元数据表中以逻辑顺序呈现，并提供了注释示例 CRF（如果可用）。此外，实施者被建议参考《创建数据收集工具的最佳实践》（最佳实践建议），以讨论案例报告表字段排序的最佳实践。

In order to facilitate classification of the different types of data collection fields, the following categories were used:
为了方便对不同类型的数据收集领域进行分类，使用了以下类别：

• Highly Recommended (HR): A data collection field that should always be on the CRF (e.g., the data are needed to meet a regulatory requirement or are required to create a meaningful dataset).
  强烈推荐（HR）：一个数据收集领域，应该始终出现在 CRF 上（例如，这些数据是满足监管要求所需，或是创建有意义的数据集所必需的）。
• Recommended/Conditional (R/C): A data collection field that should be on a CRF based on certain conditions (e.g., complete date of birth is preferred, but may not be allowed in some regions; AE time should be captured only if there is another data point with which to compare it). For any recommended/conditional fields, the "condition" is described in the "Implementation Notes" portion of the CDASHIG Metadata Table.
  推荐/条件 (R/C)：根据某些条件应在 CRF 上包含的数据收集字段（例如，完整的出生日期是首选，但在某些地区可能不被允许；不良事件时间仅在有其他数据点可供比较时捕获）。对于任何推荐/条件字段，“条件”在 CDASHIG 元数据表的“实施说明”部分中描述。
• Optional (O): A data collection field that is available for use.
  可选 (O)：可供使用的数据收集字段。

The CDASH team initially considered utilizing the SDTMIG Core Designations of Required, Expected, and Permissible to capitalize on prior understanding of these descriptive designations as well as to enable a consistent categorization across CDASH and SDTM standards. Yet, when the CDASHIG Metadata Table was constructed, it quickly became apparent that CDASHIG core designations would often differ from SDTMIG core designations due to the inherent differences between the manner in which data are collected (to ensure the most accurate data) and the structure in which data are reported and submitted. For example, a variable categorized as Required in the SDTMIG may not be required in the CDASHIG if it can be derived in the SDTM datasets (rather than be a field captured explicitly on a CRF). Also, the SDTMIG core designation of "Required" imposes a rule that the variable cannot be null. CDASHIG Core designations are not intended to impose any rules that require a field to be populated with data. They are only intended to designate which fields should be present on the CRF.
CDASH 团队最初考虑利用 SDTMIG 核心标识的“必需”、“预期”和“允许”来利用对这些描述性标识的先前理解，并实现 CDASH 和 SDTM 标准之间的一致分类。然而，当 CDASHIG 元数据表构建时，很快就显现出 CDASHIG 核心标识往往会与 SDTMIG 核心标识不同，这主要是由于数据收集方式（以确保数据的准确性）和数据报告及提交结构之间的固有差异。例如，在 SDTMIG 中被分类为“必需”的变量，如果可以在 SDTM 数据集中推导出来（而不是在 CRF 上明确捕获的字段），那么在 CDASHIG 中可能并不是必需的。此外，SDTMIG 核心标识“必需”规定该变量不能为 null。CDASHIG 核心标识并不打算强加任何要求字段必须填充数据的规则。它们仅旨在指定 CRF 上应存在哪些字段。

Adding new collection fields is often constrained by business rules, as well as by clinical data standards SMEs, clinical data management processes, and EDC systems. The naming conventions and other variable creation recommendations in CDASHIG are designed to allow collection of data regardless of subsequent inclusion in SDTM, as well as to consistently facilitate transforming the collected data into submission datasets.
添加新的收集字段通常受到业务规则的限制，以及临床数据标准的主题专家、临床数据管理流程和电子数据采集系统的影响。CDASHIG 中的命名约定和其他变量创建建议旨在允许数据的收集，无论其是否随后包含在 SDTM 中，并且始终有助于将收集的数据转换为提交数据集。

Prior to adding any new fields to current domain models, the CDASH Model should be reviewed to see if there is a root field that will work for the data collection need.
在向当前领域模型添加任何新字段之前，应审查 CDASH 模型，以查看是否有适合数据收集需求的根字段。

New data collection fields (not already defined in a CDASH Model) will fall under one of following categories.
新的数据收集字段（在 CDASH 模型中尚未定义）将属于以下类别之一。

• Fields used for data cleaning purposes only and not submitted in SDTM datasets (e.g., --YN). The field --YN with Question Text "Were there any [interventions/events/findings]?" can be added to a domain for this purpose. Replace the two dashes (--) with the two-character domain code, and create the Question Text or Prompt using generic Question Text or Prompt from the CDASH Model as a base. Always create custom data cleaning/operational variables using consistent naming conventions.
  仅用于数据清理目的的字段，不会提交到 SDTM 数据集中（例如，--YN）。字段--YN 的提问文本为“是否有任何[干预/事件/发现]？”可以为此目的添加到一个领域中。将两个破折号（--）替换为两个字符的领域代码，并使用 CDASH 模型中的通用提问文本或提示作为基础创建提问文本或提示。始终使用一致的命名约定创建自定义数据清理/操作变量。
• Fields with a direct mapping to an SDTMIG variable. If a value can be collected exactly as it will be reported in the SDTM dataset (i.e., same value, same datatype, same meaning, same Controlled Terminology), the SDTMIG variable name should be used as part of the data collection variable name in the operational database to streamline the mapping process. Any collection variable whose meaning is the same as an SDTMIG variable should be a copy of the SDTMIG variable, and the meaning should not be modified for data collection.
  与 SDTMIG 变量直接映射的字段。如果一个值可以完全按照将在 SDTM 数据集中报告的方式收集（即，相同的值、相同的数据类型、相同的含义、相同的受控术语），则应将 SDTMIG 变量名称作为操作数据库中数据收集变量名称的一部分，以简化映射过程。任何其含义与 SDTMIG 变量相同的收集变量都应是 SDTMIG 变量的副本，并且在数据收集时不应修改其含义。
• Fields without a direct one-to-one mapping to SDTM datasets. If a study requires a field that is not identical to an SDTMIG field, for example the collected data type is different from the data type in the corresponding SDTMIG variable, or the SDTMIG variable is derived from collected data, the operational database should use a variable with a different name from the SDTMIG variable into which it will be mapped.
  与 SDTM 数据集没有直接一对一映射的字段。如果研究需要一个与 SDTMIG 字段不完全相同的字段，例如收集的数据类型与相应的 SDTMIG 变量中的数据类型不同，或者 SDTMIG 变量是从收集的数据中派生的，则操作数据库应使用一个与将要映射的 SDTMIG 变量不同名称的变量。
  
  • Example 1: A study collects Findings data in a denormalized format and then maps the data to the normalized SDTM structure. The --TESTCD values can be used as the CDASHIG variable names, and the corresponding --TEST value can be used as the prompt on the CRF (See Section 8.3 General CDASH Assumptions for Findings Domains for more information).
    示例 1：一项研究以非规范化格式收集结果数据，然后将数据映射到规范化的 SDTM 结构。--TESTCD 值可以用作 CDASHIG 变量名称，相应的 --TEST 值可以用作 CRF 上的提示（有关结果领域的一般 CDASH 假设的更多信息，请参见第 8.3 节）。
  • Example 2: Dates and times are collected in a local format, familiar to the CRF users, and then reported in the SDTM-specified ISO 8601 format. In the operational database, the CDASH variables --DAT and --TIM (if collected) map into the single SDTM variable (--DTC).
    示例 2：日期和时间以本地格式收集，方便 CRF 用户使用，然后以 SDTM 指定的 ISO 8601 格式报告。在操作数据库中，CDASH 变量 --DAT 和 --TIM（如果收集）映射到单个 SDTM 变量 (--DTC)。
  • Example 3: If the mapping to SDTM is similar, but not direct, "C" can be included before the root variable name to indicate a "collected" version of the variable to which that data will map.
    示例 3：如果映射到 SDTM 是相似的，但不是直接的，可以在根变量名称前加上 "C"，以表示该数据将映射到的变量的 "收集" 版本。

    For example, if an injection is to be administered to a subject's LEFT THIGH, RIGHT THIGH, LEFT ARM, or RIGHT ARM, the sponsor may create the variable EXCLOC. The SDTM mapping would split these into EXLOC and EXLAT. That would avoid having to split the collection of the data into two fields on the CRF.
    例如，如果要对受试者的左大腿、右大腿、左臂或右臂进行注射，赞助商可以创建变量 EXCLOC。SDTM 映射将这些分为 EXLOC 和 EXLAT。这样可以避免在 CRF 上将数据收集拆分为两个字段。

This section provides an explanation of the columns used in the CDASH Model.
本节提供了 CDASH 模型中使用的列的解释。

• Observation Class: This column contains the SDTM Class for the domain.
  观察类别：此列包含该领域的 SDTM 类别。
• Domain: This column contains the two-letter domain code.
  域：此列包含两个字母的域代码。
• CDASH Variable: This column provides the CDASH root variable names (e.g., --ONGO, --DAT).
  CDASH 变量：此列提供 CDASH 根变量名称（例如，--ONGO，--DAT）。
• CDASH Variable Label: This column contains a suggested root variable label that that may be used for the CDASHIG variable.
  CDASH 变量标签：此列包含可用于 CDASHIG 变量的建议根变量标签。
• Draft CDASH Definition: This column provides a draft definition of the root variable. This text may or may not mirror any text in the SDTM. Currently, there is a new CDASH/SDTM team creating variable definitions. Once these definitions are finalized, the CDASH definitions will be updated to harmonize with them.
  草案 CDASH 定义：此列提供根变量的草案定义。该文本可能与 SDTM 中的任何文本相符，也可能不相符。目前，有一个新的 CDASH/SDTM 团队正在创建变量定义。一旦这些定义最终确定，CDASH 定义将会更新以与之协调。
• Question Text: This column in the CDASH Model contains the recommended question text for the data collection field. Question Text is a complete sentence. Some text is presented inside brackets [ ] or parentheses (). The text inside the brackets should be replaced with protocol-specified verbiage. The text inside the parentheses is optional. Text separated with a forward slash indicates optional wording from which the sponsor may choose.
  问题文本：CDASH 模型中的这一列包含数据收集字段的推荐问题文本。问题文本是一个完整的句子。一些文本以方括号 [ ] 或圆括号 () 的形式呈现。方括号内的文本应替换为协议指定的措辞。圆括号内的文本是可选的。用斜杠分隔的文本表示赞助方可以选择的可选措辞。
• Prompt: This column in the CDASH Model contains the recommended prompt text for the data collection field. The Prompt is a short version of the question. Some text is presented inside brackets [ ] or parentheses (). The text inside the brackets should be replaced with protocol-specified verbiage. The text inside the parentheses is optional. Text separated with a forward slash indicates optional wording from which the sponsor may choose.
  提示：CDASH 模型中的此列包含数据收集字段的推荐提示文本。提示是问题的简短版本。一些文本以方括号 [ ] 或圆括号 () 的形式呈现。方括号内的文本应替换为协议指定的措辞。圆括号内的文本是可选的。用斜杠分隔的文本表示赞助商可以选择的可选措辞。
• Data Type: This column contains the simple data type of the CDASH variable (e.g., Char, Num, Date, or Time).
  数据类型：此列包含 CDASH 变量的简单数据类型（例如，字符、数字、日期或时间）。
• SDTM Target: This column provides the suggested mapping to the SDTM root variable. When no direct mapping to an SDTM root variable is available, the column contains "N/A". When the column contains "SUPP--.QNAM", it means that the value represented in the CDASH variable shall be mapped to an SDTM Supplemental Qualifier. NOTE: CDASH variables noted as not having a direct map to SDTM variables (i.e., non standard variables) may have SDTM variable equivalents in future versions.
  SDTM 目标：此列提供建议的映射到 SDTM 根变量。当没有直接映射到 SDTM 根变量时，该列包含“N/A”。当该列包含“SUPP--.QNAM”时，意味着 CDASH 变量中表示的值应映射到 SDTM 补充限定符。注意：标记为没有直接映射到 SDTM 变量的 CDASH 变量（即非标准变量）在未来版本中可能会有 SDTM 变量的对应项。
  
• Mapping Instructions: This column contains information on the suggested mapping of the root variable to the SDTM variable.
  映射说明：此列包含有关根变量与 SDTM 变量建议映射的信息。
• Controlled Terminology Codelist Name: This column contains the Controlled Terminology (CT) codelist name {e.g., (LOC)} that is associated with the field. Certain variables (e.g., dates) use ISO formats as CT, however in CDASH these variables are generally not collected using the ISO CT. These variables are converted to the ISO format when the SDTM-based submission datasets are created.
  受控术语代码列表名称：此列包含与该字段相关的受控术语（CT）代码列表名称 {例如，（LOC）}。某些变量（例如，日期）使用 ISO 格式作为 CT，但在 CDASH 中，这些变量通常不使用 ISO CT 进行收集。当创建基于 SDTM 的提交数据集时，这些变量会转换为 ISO 格式。
• Implementation Notes: This column contains further information, such as rationale and implementation instructions, on how to implement the CRF data collection fields and how to map CDASH variables to SDTM variables.
  实施说明：本栏包含有关如何实施 CRF 数据收集字段以及如何将 CDASH 变量映射到 SDTM 变量的进一步信息，例如理由和实施说明。

Note: When multiple options are contained in a single cell, the options are separated by a semicolon.
注意：当一个单元格中包含多个选项时，选项之间用分号分隔。

This section provides an explanation of the columns used in the CDASHIG Metadata Table.
本节提供了 CDASHIG 元数据表中使用的列的解释。

• Observation Class: This column contains the SDTM Class for the domain.
  观察类别：此列包含该领域的 SDTM 类别。
• Domain: This column contains the two-letter domain code.
  域：此列包含两个字母的域代码。
• Data Collection Scenario: This column in the CDASHIG Metadata Table identifies the different data collection options in CDASH for the same domain and is best used for filtering the table. The information in this column provides the context for the CDASHIG Core Designations, e.g., denoting which fields should be present on the CRF. When only one data collection scenario is provided for the domain, the column contains "N/A".
  数据收集场景：CDASHIG 元数据表中的这一列标识了同一领域中 CDASH 的不同数据收集选项，最适合用于过滤表格。该列中的信息为 CDASHIG 核心指定提供了背景，例如，指明哪些字段应出现在 CRF 上。当该领域仅提供一个数据收集场景时，该列包含“N/A”。
• Implementation Options: When this column contains "Horizontal-Generic", a sampling of the CDASHIG metadata is provided as a template for the metadata of the CRF in a denormalized structure. When this column contains "Horizontal-Example", it represents a specific execution of CRF metadata in a denormalized structure.
  实施选项：当此列包含“水平-通用”时，提供 CDASHIG 元数据的采样作为 CRF 元数据的模板，采用非规范化结构。当此列包含“水平-示例”时，它表示 CRF 元数据在非规范化结构中的特定执行。
• Order Number: This column provides a suggested order of CDASHIG variables to be displayed on a CRF.
  订单编号：此列提供建议的 CDASHIG 变量顺序，以便在 CRF 上显示。
• CDASHIG Variable: This column provides the CDASHIG variable names (e.g., CMONGO, AEDAT).
  CDASHIG 变量：此列提供 CDASHIG 变量名称（例如，CMONGO，AEDAT）。
• CDASHIG Variable Label: This column provides the CDASHIG variable label.
  CDASHIG 变量标签：此列提供 CDASHIG 变量标签。
• Draft CDASHIG Definition: This column provides a draft definition of the CDASHIG variable. This text may or may not mirror any text in the SDTMIG. Currently, there is a new CDASH/SDTM team creating variable definitions. Once these definitions are finalized, the CDASH definitions will be updated to harmonize with them.
  草案 CDASHIG 定义：此列提供 CDASHIG 变量的草案定义。该文本可能与 SDTMIG 中的任何文本相符，也可能不相符。目前，有一个新的 CDASH/SDTM 团队正在创建变量定义。一旦这些定义最终确定，CDASH 定义将会更新以与之协调。
• Question Text: This column in the CDASHIG Metadata Table provides the suggested text for the specific Domain. Implementers should refer to the CDASH Model to create alternative question text that may be used that meets the CDASH conformance rules. Question Text is a complete sentence. Some text is presented inside brackets [ ] or parentheses (). The text inside the brackets should be replaced with protocol-specified verbiage. The text inside the parentheses is optional. Text separated with a forward slash indicates optional wording from which the sponsor may choose.
  该 CDASHIG 元数据表中的这一列提供了特定领域的建议文本。实施者应参考 CDASH 模型创建符合 CDASH 一致性规则的替代问题文本。问题文本是一个完整的句子。一些文本以方括号 [ ] 或圆括号 ( ) 的形式呈现。方括号内的文本应替换为协议指定的措辞。圆括号内的文本是可选的。用斜杠分隔的文本表示赞助方可以选择的可选措辞。
• Prompt: This column in the CDASHIG Metadata Table provides the suggested text for the specific Domain. Implementers should refer to the CDASH Model to create alternative prompt text that may be used that meets the CDASH conformance rules The Prompt is a short version of the question. Some text is presented inside brackets [ ] or parentheses (). The text inside the brackets should be replaced with protocol-specified verbiage.
  该 CDASHIG 元数据表中的这一列提供了特定领域的建议文本。实施者应参考 CDASH 模型创建符合 CDASH 一致性规则的替代提示文本。提示是问题的简短版本。一些文本以方括号 [ ] 或圆括号 () 的形式呈现。方括号内的文本应替换为协议指定的用语。
• Data Type: This column contains the simple data type of the CDASH variable (e.g., Char, Num, Date, or Time).
  数据类型：此列包含 CDASH 变量的简单数据类型（例如，字符、数字、日期或时间）。
• CDASHIG Core: This column contains the CDASHIG core designations for basic data collection fields (i.e., Highly Recommended (HR), Recommended/Conditional (R/C), Optional (O)). See Section 3.3 for definitions of CDASH core designations.
  CDASHIG 核心：此列包含基本数据收集字段的 CDASHIG 核心标识（即，高度推荐（HR）、推荐/有条件（R/C）、可选（O））。有关 CDASH 核心标识的定义，请参见第 3.3 节。
• Case Report Form Completion Instructions: This column contains recommended example instructions for the clinical site on how to enter collected information on the CRF.
  病例报告表填写说明：本栏目包含临床现场关于如何在病例报告表上输入收集信息的推荐示例说明。
• SDTMIG Target: This column provides the suggested mapping to the SDTMIG variable name. It may help facilitate the creation of the SDTMIG variables needed for submission. When no direct mapping to an SDTMIG variable is available the column contains "N/A". When the column contains "SUPP--.QNAM", it means that that the value represented in the CDASH field shall be mapped to an SDTM Supplemental Qualifier. NOTE: CDASHIG variables noted as not having a direct map to SDTMIG variables (i.e., non standard variables) may have SDTM variable equivalents in future versions.
  SDTMIG 目标：此列提供了建议的 SDTMIG 变量名称映射。它可能有助于创建提交所需的 SDTMIG 变量。当没有直接映射到 SDTMIG 变量时，该列包含 "N/A"。当该列包含 "SUPP--.QNAM" 时，意味着 CDASH 字段中表示的值应映射到 SDTM 补充限定符。注意：CDASHIG 变量被标记为没有直接映射到 SDTMIG 变量（即非标准变量），在未来版本中可能会有 SDTM 变量的对应项。
• Mapping Instructions: This column contains information on the suggested mapping of the CDASHIG variable to the SDTMIG variable. Mapping instructions in the CDASHIG Metadata Table provide more complete guidance than those present in the CDASH Model. When domain level metadata are not available, consult the Model for SDTM Mapping Instructions.
  映射说明：此列包含有关将 CDASHIG 变量映射到 SDTMIG 变量的建议信息。CDASHIG 元数据表中的映射说明提供的指导比 CDASH 模型中的更为全面。当域级元数据不可用时，请参考 SDTM 映射说明模型。
• SDTMIG Core: This column contains the SDTMIG core designations (i.e., Required (Req), Expected (Exp), and Permissible (Perm)). The CDASHIG core designations differ from SDTMIG core designations. A Required variable in the SDTMIG may not be Highly Recommended in the CDASHIG.
  SDTMIG 核心：此列包含 SDTMIG 核心标识（即，必需（Req）、预期（Exp）和允许（Perm））。CDASHIG 核心标识与 SDTMIG 核心标识不同。SDTMIG 中的必需变量在 CDASHIG 中可能不是高度推荐的。
• Controlled Terminology Codelist Name: This column contains the Controlled Terminology (CT) codelist name {e.g., (LOC)} that is associated with the field. The SDTMIG indicates that certain variables (e.g., dates) use ISO formats as CT, however in CDASH these variables are generally not collected using the ISO CT. These variables are converted to the ISO format when the SDTM-based submission datasets are created.
  受控术语代码列表名称：此列包含与该字段相关的受控术语（CT）代码列表名称{例如，（LOC）}。SDTMIG 指出某些变量（例如，日期）使用 ISO 格式作为 CT，但在 CDASH 中，这些变量通常不是使用 ISO CT 收集的。当创建基于 SDTM 的提交数据集时，这些变量会转换为 ISO 格式。
• Subset Controlled Terminology/CDASH Codelist Name: This column contains the CDISC Controlled Terminology or CDASH Subset Codelist name that may be used for that specific variable (e.g., EXDOSFRM).
  子集控制术语/CDASH 代码列表名称：此列包含可用于特定变量的 CDISC 控制术语或 CDASH 子集代码列表名称（例如，EXDOSFRM）。
• Implementation Notes: This column contains further information, such as rationale and implementation instructions, on how to implement the CRF data collection fields and how to map CDASHIG variables to SDTMIG variables.
  实施说明：本栏包含有关如何实施 CRF 数据收集字段的进一步信息，例如理由和实施说明，以及如何将 CDASHIG 变量映射到 SDTMIG 变量。

Note: When multiple options are contained in a single cell, the options are separated by a semicolon.
注意：当一个单元格中包含多个选项时，选项之间用分号分隔。

Collection of Dates: Collect dates in such a way to allow the sites to record only the precision they know. The system should also store only the collected precision. Any incomplete dates must remain incomplete with no imputation and no "zero-filling" of missing components.
日期收集：以允许站点仅记录他们所知道的精度的方式收集日期。系统还应仅存储收集到的精度。任何不完整的日期必须保持不完整，不得进行插补，也不得对缺失的组件进行“零填充”。

Data collection and database processes should allow for the possibility of partial dates and times, since a partial date may be the most precise information that can be collected for some data. An example of when it may be necessary or appropriate to collect partial dates is found in the DM domain. In some countries, collection of a complete date of birth is restricted under privacy rules, so only a year, or year and month of birth might be collected. Other examples of commonly collected partial dates are found in CM and MH, where the subject may not remember the complete date of when they started to take a medication or when a significant medical history condition began.
数据收集和数据库处理应允许部分日期和时间的可能性，因为对于某些数据，部分日期可能是可以收集到的最精确的信息。在 DM 领域中，有时收集部分日期是必要或合适的例子。在某些国家，出于隐私规则，完整的出生日期的收集受到限制，因此可能只收集出生的年份或年份和月份。其他常见的部分日期收集例子出现在 CM 和 MH 中，受访者可能不记得他们开始服用药物的完整日期或某个重要医疗历史状况开始的完整日期。

If a full date is collected, the CDASH variable --DAT or all three date components (--DATYY, --DATMO, and --DATDD) should be included on the collection tool. If a partial date can be collected in a single field, the CDASH --DAT should be used. If a partial date must be collected as separate database fields to collect year, month and day, refer to the CDASH Model for examples of standard naming fragments (--YY, --MO, --DD, --TIM). The capabilities of individual software systems (e.g., EDC) will determine which variable names are needed. CDASH uses separate data collection fields for dates and times. If times are collected, it is expected that they will be used with the appropriate collected date to derive the related SDTM date variable in ISO8601 format.
如果收集了完整的日期，则应在收集工具中包含 CDASH 变量--DAT 或所有三个日期组件（--DATYY、--DATMO 和--DATDD）。如果可以在单个字段中收集部分日期，则应使用 CDASH --DAT。如果必须将部分日期作为单独的数据库字段收集以获取年、月和日，请参考 CDASH 模型以获取标准命名片段的示例（--YY、--MO、--DD、--TIM）。各个软件系统（例如，EDC）的功能将决定需要哪些变量名称。CDASH 为日期和时间使用单独的数据收集字段。如果收集了时间，预计将与适当收集的日期一起使用，以推导出相关的 SDTM 日期变量，格式为 ISO8601。

Conversion of Dates for Submission: See section SDTMIG v3.2 Sections 4.1.4.1 and 4.1.4.2 for detailed information about converting dates and times from the collection format to the submission format using ISO 8601. A specific example of mapping birth date is shown here.
提交日期的转换：有关使用 ISO 8601 将日期和时间从收集格式转换为提交格式的详细信息，请参见 SDTMIG v3.2 第 4.1.4.1 节和第 4.1.4.2 节。这里展示了一个出生日期映射的具体示例。

The SDTM date format allows this partial date to be submitted so the reviewer can see what was collected.
SDTM 日期格式允许提交部分日期，以便审阅者可以查看所收集的信息。

Imputation of Dates: If the missing parts of the date are imputed for analysis purposes, the imputed dates will be generated in the analysis data (ADaM) but not in the SDTM submission data sets.
日期的推算：如果为了分析目的对缺失的日期部分进行推算，推算出的日期将会在分析数据（ADaM）中生成，但不会出现在 SDTM 提交数据集中。

Relative Timing variables are sets of variables that provide information about how the timing of the record relates to either the study reference period or another fixed point in time. The CDASH Relative Timing variables are collected for those observations where a date is either not collected or is not available. The CDASH set of variables serve as an indicator (or flag) that the observation's "start" was "prior" to the study reference period or prior to another fixed point in time OR that the observation's "end" was "after" or "ongoing" as of the study reference period or another fixed point in time. The CDASH variables of --PRIOR and --ONGO serve this purpose. How these CDASH "flags" are translated to SDTM (according to controlled terminology) depends on whether the comparison is against the protocol-defined study reference period or against another fixed point in time that may serve as the "reference" for the timing of the record. To emphasize, the collection of these CDASH relative timing variables are always dependent on the actual date either being prospectively "not collected" or not available. Much more information can be found under the "General Assumptions" for both Interventions and Events domains.
相对时间变量是一组变量，提供有关记录的时间如何与研究参考期或另一个固定时间点相关的信息。CDASH 相对时间变量用于那些未收集日期或日期不可用的观察。CDASH 变量集作为指示（或标志），表明观察的“开始”是在研究参考期之前或在另一个固定时间点之前，或者观察的“结束”是在研究参考期之后或在研究参考期时仍在进行。CDASH 变量--PRIOR 和--ONGO 用于此目的。这些 CDASH“标志”如何转换为 SDTM（根据受控术语）取决于比较是针对协议定义的研究参考期，还是针对可能作为记录时间“参考”的另一个固定时间点。需要强调的是，这些 CDASH 相对时间变量的收集始终依赖于实际日期是否前瞻性地“未收集”或不可用。 在干预和事件领域的“一般假设”下可以找到更多信息。

For all SDTM submissions, there is a defined period during which the subject is considered to be "on study". According to the SDTMIG v3.2, the start and end dates of the "on study" period are submitted in the variables RFSTDTC and RFENDTC. The defined period may be protocol-specific or set by company policy, SOPs, or other documented procedures. The "on study" period might be defined as being from the date/time of Informed Consent through the date/time of subject's completion of the study, or it might be from the date/time of first dose to the date/time of last dose. Regardless of how the "on study" period is defined, the dates (and optionally times) of the start and end of that period must be collected.
对于所有 SDTM 提交，有一个定义的时间段，在此期间受试者被视为“在研究中”。根据 SDTMIG v3.2，“在研究中”期间的开始和结束日期在变量 RFSTDTC 和 RFENDTC 中提交。该定义的时间段可能是特定于方案的，或由公司政策、标准操作程序（SOP）或其他文档化程序设定。“在研究中”期间可能被定义为从知情同意的日期/时间到受试者完成研究的日期/时间，或者可能是从第一次给药的日期/时间到最后一次给药的日期/时间。无论“在研究中”期间如何定义，该期间的开始和结束日期（可选时间）必须被收集。

If there is a need to collect information about whether an observation of interest occurred prior to a reference point or milestone other than the beginning of the study, or was ongoing or continuing at some reference point or milestone in the study other than the end of the defined "on study" period, the date/time of that reference point or milestone should also be collected. If this date/time has been collected, reasonable comparisons can be made to that date/time with "prior", "coincident", "continuing", or "ongoing" questions.
如果需要收集有关某个感兴趣的观察是否在研究开始之前的参考点或里程碑发生，或者在研究中某个参考点或里程碑时是否正在进行或持续，应该收集该参考点或里程碑的日期/时间。如果已收集该日期/时间，可以对该日期/时间与“之前”、“同时”、“持续”或“进行中”的问题进行合理比较。

The following steps should be taken to ensure observations of interest that occur over time can be related to the study period or to fixed point in time or a milestone in a meaningful way. Chart 1 below provides a representation of an intervention as it relates to the study reference period, and Charts 2 and 3 provide a representation of comparisons as it relates to other fixed points in time or a milestone.
以下步骤应采取，以确保随时间发生的感兴趣观察可以以有意义的方式与研究期间、固定时间点或里程碑相关联。下面的图表 1 提供了干预与研究参考期间的关系表示，图表 2 和图表 3 提供了与其他固定时间点或里程碑的比较表示。

Study Reference Period (Chart 1)
研究参考期（图表 1）

1. Define the "on study" period.(B-C). Once the overall "on study" period has been defined (B-C), collect the dates (/times) of the start of the study reference period (e.g., date of informed consent, date of first dose) and end of the study reference period (e.g., date of last contact, date of last dose), as part of the clinical data with their respective domains (e.g., DS, EX). These dates will map into the RFSTDTC (B) (start of Study Reference Period) and RFENDTC (C) (end of Study Reference Period) variables in the SDTMIG DM dataset.
   定义“研究期间”（B-C）。一旦整体“研究期间”被定义（B-C），收集研究参考期开始的日期（时间）（例如，知情同意日期、首次给药日期）和研究参考期结束的日期（时间）（例如，最后联系日期、最后给药日期），作为临床数据的一部分及其各自的领域（例如，DS，EX）。这些日期将映射到 SDTMIG DM 数据集中 RFSTDTC（B）（研究参考期开始）和 RFENDTC（C）（研究参考期结束）变量。

2. Collected comparisons ((D, E) using CDASHIG variables (e.g., "prior", "ongoing") of when something started or ended in relation to the "on study" reference period (i.e., RFSTDTC-RFENDTC: (B-C). These CDASH variables are used to populate the SDTMIG variables--STRF and --ENRF variables when the SDTM-based datasets are created. (Note: these relative timing variables are only populated in the SDTM -based datasets when a date is not collected.).
   收集的比较（（D，E）使用 CDASHIG 变量（例如，“之前”，“进行中”）来表示某事在“研究期间”参考期（即 RFSTDTC-RFENDTC：（B-C））的开始或结束时间。这些 CDASH 变量用于在创建基于 SDTM 的数据集时填充 SDTMIG 变量--STRF 和--ENRF 变量。（注意：这些相对时间变量仅在未收集日期时填充到基于 SDTM 的数据集中。）

Fix point in Time/Milestone (Charts 2, 3)
时间/里程碑的固定点（图表 2, 3）

1. Define the fix point in time or milestone (B or C).The fix point in time or milestone can be a date or a description. This will map into either the SDTMIG variables (–STTPT or --ENTPT) when the SDTM-based datasets are created .
   定义时间固定点或里程碑（B 或 C）。时间固定点或里程碑可以是一个日期或描述。这将在创建基于 SDTM 的数据集时映射到 SDTMIG 变量（–STTPT 或--ENTPT）。
2. Collected comparisons (D or E) using CDASHIG variables (e.g., "prior", "ongoing") of when something started or ended in relation to the fixed point in time or milestone (B or C). These CDASH variables are used to populate the SDTMIG variables--STRTPT or --ENRTPT when the SDTM-based datasets are created.(Note: these relative timing variables are only populated in the SDTM -based datasets when a date is not collected).
   收集的比较（D 或 E）使用 CDASHIG 变量（例如，“之前”，“进行中”）来表示某事何时开始或结束，相对于固定时间点或里程碑（B 或 C）。这些 CDASH 变量用于填充 SDTMIG 变量--STRTPT 或--ENRTPT，当创建基于 SDTM 的数据集时。（注意：这些相对时间变量仅在未收集日期时填充到基于 SDTM 的数据集中）。

For information about mapping what is collected in "prior", "ongoing", and "continuing" fields into the appropriate SDTMIG variables, see the SDTMIG V3.2 Section 4.1.4.7.
有关将“先前”、“进行中”和“持续”字段中收集的内容映射到适当的 SDTMIG 变量的信息，请参见 SDTMIG V3.2 第 4.1.4.7 节。

Submission data standards are required by some global regulators, and controlled terminology (CT) is part of the requirement. Using CT from the start during data collection builds in traceability and transparency, and reduces the problems associated with trying to convert legacy codelists and variables to the submission standards. CT can be used in the following ways during data collection:
提交数据标准是一些全球监管机构所要求的，受控术语（CT）是其中的一部分。在数据收集的初始阶段使用 CT 可以建立可追溯性和透明度，并减少将遗留代码列表和变量转换为提交标准时所遇到的问题。在数据收集过程中，CT 可以以以下方式使用：

1. To collect data using a standardized list of values (e.g., Mild, Moderate, Severe)
   使用标准化的数值列表（例如：轻度、中度、重度）收集数据
2. To ask a specific question on the CRF (e.g., Temperature)
   在 CRF 上提出具体问题（例如，温度）
3. To create a variable name in the database (e.g., TEMP for the collection of vital sign data when a unique variable name must be created for each vital sign result.)
   在数据库中创建一个变量名（例如，TEMP，用于收集生命体征数据时，当每个生命体征结果必须创建一个唯一的变量名时）。

Terminology applicable to CDASH data collection fields is either in production or under development by the CDISC Terminology Team. Production terminology is published by the National Cancer Institute's Enterprise Vocabulary Services (NCI EVS) and can be accessed via the following link: http://www.cancer.gov/cancertopics/terminologyresources/CDISC. The examples in this document use CDISC controlled terminology where possible, but some values that seem to be controlled terminology may still be under development at the time of publication, or even especially plausible "best guess" placeholder values. Do not rely on any source other than the CDISC value set in the NCI Thesaurus for controlled terminology.
适用于 CDASH 数据收集字段的术语要么在生产中，要么由 CDISC 术语团队开发中。生产术语由国家癌症研究所的企业词汇服务（NCI EVS）发布，可以通过以下链接访问：http://www.cancer.gov/cancertopics/terminologyresources/CDISC。本文档中的示例尽可能使用 CDISC 控制术语，但一些看似控制术语的值在发布时可能仍在开发中，或者甚至是特别合理的“最佳猜测”占位符值。请不要依赖于 NCI 词库中 CDISC 值集以外的任何来源作为控制术语。

In some cases it is more appropriate to use a subset of a published SDTM terminology list, rather than the entire list. To begin with an established subset of the SDTM terminology, go to https://www.cancer.gov/research/resources/terminology/cdisc and reference the CDASH terminology. These CDASH codelists have been subsetted from the complete SDTM terminology lists and are available to implementers as a way to quickly set up codelists for data collection. However, most implementers will also need to review the SDTM terminology to determine which other values are needed for their particular implementation. The CDASH terminology subset names are provided in the CDASHIG Metadata Table for easy reference.
在某些情况下，使用已发布的 SDTM 术语列表的子集比使用整个列表更为合适。要开始使用已建立的 SDTM 术语子集，请访问 https://www.cancer.gov/research/resources/terminology/cdisc 并参考 CDASH 术语。这些 CDASH 代码列表是从完整的 SDTM 术语列表中提取的，供实施者快速设置数据收集的代码列表。然而，大多数实施者还需要审查 SDTM 术语，以确定其特定实施所需的其他值。CDASH 术语子集名称在 CDASHIG 元数据表中提供，便于参考。

Some codelists, such as Laboratory Test Codes (LBTESTCD), are extensible. This means that values that are not already represented in that list (either as a CDISC Submission Value, a synonym or an NCI preferred term) may be added as needed. Other codelists, such as AE Action Taken with Study Treatment, are non-extensible and must be used without adding any terms to the list. If gaps are indentified, sponsors should submit requests to add values to controlled terminology by using the New Term Request form found at http://ncitermform.nci.nih.gov/ncitermform/?version=cdisc.
某些代码列表，例如实验室测试代码（LBTESTCD），是可扩展的。这意味着可以根据需要添加在该列表中尚未表示的值（无论是作为 CDISC 提交值、同义词还是 NCI 首选术语）。其他代码列表，例如与研究治疗相关的 AE 采取的行动，是不可扩展的，必须在不向列表中添加任何术语的情况下使用。如果发现缺口，赞助商应通过使用位于 http://ncitermform.nci.nih.gov/ncitermform/?version=cdisc 的新术语请求表单提交请求，以将值添加到受控术语中。

In cases where a CDASH/CDASHIG variable has associated controlled terminology, the codelist is referenced in Controlled Terminology column in the CDASH Model and CDASHIG Metadata Table in this format: (codelist name).
在 CDASH/CDASHIG 变量有相关控制术语的情况下，代码列表在 CDASH 模型和 CDASHIG 元数据表的控制术语列中以以下格式引用：（代码列表名称）。

CDASH Best Practices describe operational recommendations to support data collection, suggested CRF development workflow, and methods for creating data collections instruments. The first section, Best Practices for Creating Data Collection Instruments, is part of conformance to the CDASH Standard.
CDASH 最佳实践描述了支持数据收集的操作建议、建议的 CRF 开发工作流程以及创建数据收集工具的方法。第一部分，创建数据收集工具的最佳实践，是符合 CDASH 标准的一部分。

The recommendations are general principles that may be implemented during CRF form design and/or database set up in different ways, depending on the systems used.
这些建议是一般原则，可以根据使用的系统以不同方式在 CRF 表单设计和/或数据库设置中实施。

Providing the clinical site with a consistent and clinically logical order of these fields will reduce data entry time and result in more reliable data. Therefore, the CRF should be quick and easy for site personnel to complete.
为临床现场提供一致且符合临床逻辑的字段顺序将减少数据录入时间，并提高数据的可靠性。因此，CRF 应该便于现场人员快速、轻松地完成。

Clinical Operations staff should review the CRF for compatibility with common site workflow and site procedures.
临床运营人员应审查 CRF，以确保其与常见现场工作流程和现场程序的兼容性。

When a binary response is expected, "Yes/No" responsesare preferred over "Check all that apply", becausea missing response could lead to a misinterpretation of critical data. For example, if AEsare determined to be serious based only upon checking the applicable serious criteria (e.g., Hospitalization, Congenital Anomaly, etc.), failure to check a criterion would delay identification of an SAE.
当期望二元响应时，"是/否"的回答比"检查所有适用项"更为优选，因为缺失的响应可能导致对关键数据的误解。例如，如果仅根据勾选适用的严重标准（例如，住院、先天性畸形等）来判断不良事件的严重性，未勾选某一标准将延迟对严重不良事件的识别。

Conformance means that: 符合性意味着：

1. Core designations must be followed: All Highly Recommended and applicable Recommended/Conditional Fields must be present in the CRF or available from the operational database.
   核心标识必须遵循：所有高度推荐和适用的推荐/条件字段必须在 CRF 中存在或可从操作数据库中获取。
2. CDISC Controlled Terminology must be used: The CDISC Controlled Terminology that is included in the CDASHIG Metadata Table must be used to collect the data in the CRF. All codelists displayed in the CRF must use or directly map to the current published CDISC Controlled Terminology submission values, when it is available. Subsets of published Controlled Terminology, such as those provided in CDASH terminology, can be used.
   CDISC 控制术语必须使用：在 CRF 中收集数据时，必须使用包含在 CDASHIG 元数据表中的 CDISC 控制术语。CRF 中显示的所有代码列表必须使用或直接映射到当前发布的 CDISC 控制术语提交值（如果可用）。可以使用发布的控制术语的子集，例如 CDASH 术语中提供的子集。
   1. In Findings domains, values from the relevant CDISC Controlled Terminology lists must also be used to create appropriate Question Text, Prompts and/or variable names (e.g., If the question is about the subject's height, incorporate the value of "Height" from the VSTEST codelist as the Prompt on the CRF, and incorporate "HEIGHT" from VSTESTCD in the variable name).
      在发现领域中，必须使用相关的 CDISC 控制术语列表中的值来创建适当的问题文本、提示和/或变量名称（例如，如果问题是关于受试者的身高，则在 CRF 上将“Height”从 VSTEST 代码列表中作为提示，并在变量名称中使用“HEIGHT”来自 VSTESTCD）。
3. Best practices must be followed: The design of the CRF must follow the Best Practices for Creating Data Collection Instruments and CRF Design Best Practices.
   必须遵循最佳实践：CRF 的设计必须遵循数据收集工具创建的最佳实践和 CRF 设计最佳实践。
4. The wording of the CRF questions should be standardized: CDASH Question Text or Prompt must be used to ask the question.
   CRF 问题的措辞应标准化：必须使用 CDASH 问题文本或提示来提问。
   1. In cases where the data collection is done in a denormalized presentation on the CRF, the relevant CDISC controlled terminology should be used in the Question Text or Prompt as much as possible. It is acceptable to use synonym text that will directly map to one CDISC Submission Value, including an NCI Preferred Term, if the CDISC Submission Value is not appropriate for data collection. For example, "ALT" may be better than "Alanine Aminotransferase" as the prompt for this lab test. If there is no CDISC Controlled Terminology available, the Question Text or Prompt must be standardized by the implementing organization and used consistently. One of the basic purposes of CDASH is to reduce unnecessary variability between CRFs and to encourage the consistent use of variables to support semantic interoperability; therefore, Question Text and Prompt must be used verbatim.
      在数据收集以非规范化形式在 CRF 上进行的情况下，应尽可能在问题文本或提示中使用相关的 CDISC 控制术语。如果 CDISC 提交值不适合数据收集，可以使用直接映射到一个 CDISC 提交值的同义词文本，包括 NCI 首选术语。例如，对于这个实验室测试，"ALT"可能比"丙氨酸氨基转移酶"更合适作为提示。如果没有可用的 CDISC 控制术语，问题文本或提示必须由实施组织进行标准化并保持一致。CDASH 的基本目的之一是减少 CRF 之间不必要的变异性，并鼓励一致使用变量以支持语义互操作性；因此，问题文本和提示必须逐字使用。
   2. Similarly, where SDTMIG variables may exist in the operational database and the value conforms to Controlled Terminology, it is permissible to use a familiar synonym on the CRF without affecting conformance. An example may be on the Demographics page where SEX may be displayed as "Male" or "Female", while in the operational database, the controlled terminology values of "M" and "F" would be used.
      同样，在操作数据库中可能存在 SDTMIG 变量且其值符合受控术语的情况下，可以在 CRF 上使用熟悉的同义词而不影响符合性。例如，在人口统计页面上，性别可以显示为“男性”或“女性”，而在操作数据库中，则使用受控术语值“M”和“F”。
   3. In some cases, CDASH Questions Text and Prompt allow for flexibility while still being considered conformant. See section 2.3 CRF Development Overview for further details on the usage of Question Text and Prompt.
      在某些情况下，CDASH 问题文本和提示允许灵活性，同时仍被视为符合标准。有关问题文本和提示使用的更多详细信息，请参见第 2.3 节 CRF 开发概述。
   4. The CDASH Model Question Text may contain options for the tense, but if the option is not provided, the tense of the Question Text may be modified to reflect the needs of the study.
      CDASH 模型问题文本可能包含时态选项，但如果未提供选项，问题文本的时态可能会根据研究的需要进行修改。
   5. For cases where the Question Text or Prompt cannot be used due to culture or language, or a CRF must be translated for language or cultural reasons, the implementer must ensure the translation is semantically consistent with the CDASH Question Text and Prompt in the CDASHIG Metadata Table.
      对于因文化或语言原因无法使用问题文本或提示的情况，或者由于语言或文化原因必须翻译 CRF 的情况，实施者必须确保翻译在语义上与 CDASHIG 元数据表中的 CDASH 问题文本和提示保持一致。
   6. In cases where a more specific question needs to be asked than what is provided by Question Text or Prompt, CDASH recommends the use of a brief CRF Completion Instruction, as long as the instruction clarifies the data required by the study without altering the meaning of variable as defined by the standard. For example "Sex at birth" is not the same question as "Sex" (which is loosely defined as "reported sex").
      在需要提出比问题文本或提示更具体的问题的情况下，CDASH 建议使用简短的 CRF 填写说明，只要该说明能够澄清研究所需的数据而不改变标准所定义的变量的含义。例如，“出生时性别”与“性别”并不是同一个问题（后者被宽泛定义为“报告的性别”）。
5. Variable Names: The CDASHIG variable naming conventions should be used in the operational database, using a consistent syntax that includes the root variable name and/or controlled terminology, and any other standardized concepts that are needed to support efficient mapping of the collected value to SDTM datasets. The goals are to have beginning-to-end traceability of the variable name from the data capture system to the SDTM datasets, and to support automating electronic data capture (EDC) setup and downstream processes.
   变量名称：应在操作数据库中使用 CDASHIG 变量命名约定，采用一致的语法，包括根变量名称和/或受控术语，以及支持将收集的值有效映射到 SDTM 数据集所需的其他标准化概念。目标是实现从数据捕获系统到 SDTM 数据集的变量名称的端到端可追溯性，并支持自动化电子数据捕获（EDC）设置和下游流程。
   1. It is recognized that particularly in an EDC system, the variable name of a data collection field, as well as the name in the underlying database, may have various "system" components that become part of the item's identifier. EDC systems, prior to exporting data in a defined format, may require the variable name to include such database "references" as the EDC page name, the item "group" name, or perhaps a combination.
      在电子数据采集（EDC）系统中，数据收集字段的变量名称以及底层数据库中的名称可能包含各种“系统”组件，这些组件成为项目标识符的一部分。EDC 系统在以定义格式导出数据之前，可能要求变量名称包含这些数据库“引用”，例如 EDC 页面名称、项目“组”名称或它们的组合。
   2. In cases where the data collection is done in a denormalized way, appropriate CDISC controlled terminology must be used when it is available. For example, when collecting Vital Signs results in a denormalized eCRF, the variable names can be created by using terms from the Vital Signs Test Code codelist. For example, Temperature result can be collected in a variable called TEMP or TEMP_VSORRES, Systolic Blood Pressure result, can be collected in a variable called SYSBP or SYSBP_VSORRES. When a particular system's constraints limit the variable name to 8 characters, a similar, consistent implementation that preserves either the normalized root variable (e.g., ORRES) or the controlled terminology (e.g., --TESTCD value) should be implemented.
      在数据收集以非规范化方式进行的情况下，必须在可用时使用适当的 CDISC 控制术语。例如，在非规范化的电子病例报告表（eCRF）中收集生命体征结果时，可以使用生命体征测试代码代码表中的术语来创建变量名称。例如，温度结果可以收集在名为 TEMP 或 TEMP_VSORRES 的变量中，收缩压结果可以收集在名为 SYSBP 或 SYSBP_VSORRES 的变量中。当特定系统的限制将变量名称限制为 8 个字符时，应实施类似且一致的实现，以保留规范化的根变量（例如，ORRES）或控制术语（例如，--TESTCD 值）。
   3. Whereas all CDASHIG defined variable names are 8 characters or less to accommodate SDTM limits on variable names, QNAMs, and --TESTCDs, the maximum length of a variable name that may be implemented is determined by the data management system used, not by CDASH.
      由于所有 CDASHIG 定义的变量名称都限制在 8 个字符以内，以适应 SDTM 对变量名称、QNAM 和--TESTCD 的限制，因此可实施的变量名称的最大长度由所使用的数据管理系统决定，而不是由 CDASH 决定。
6. Data Values and Format: Because an SDTM data programmer should be able to assume that data in an SDTMIG variable is SDTMIG compliant, the data output by the operational database into an SDTMIG variable ideally requires no additional processing. Minimal processing (e.g., changing case) is still conformant. This helps to ensure a quality deliverable, even if the SDTM data programmer is unfamiliar with data capture practices.
   数据值和格式：因为 SDTM 数据程序员应该能够假设 SDTMIG 变量中的数据符合 SDTMIG 标准，所以操作数据库输出到 SDTMIG 变量的数据理想情况下不需要额外处理。最小的处理（例如，改变大小写）仍然是符合要求的。这有助于确保交付物的质量，即使 SDTM 数据程序员对数据采集实践不熟悉。
7. Questionnaires: In order to maintain the validity of a validated instrument, studies that include validated questionnaires, ratings, or scales must present the questions and reply choices in the manner in which these were validated. (Reference QRS - Questionnaires, Ratings and Scales).
   问卷：为了保持经过验证的工具的有效性，包含经过验证的问卷、评分或量表的研究必须以这些工具被验证的方式呈现问题和回复选项。（参考 QRS - 问卷、评分和量表）。
   1. In some cases, this may result in CRFs that do not conform to CDASH Best Practices; however, restructuring these questionnaires should not be done because it could invalidate them.
      在某些情况下，这可能导致 CRF 不符合 CDASH 最佳实践；然而，不应重组这些问卷，因为这可能使其失效。
   2. The use of such questionnaires in their native format should not be considered to affect conformance to CDASH.
      使用这些问卷的原始格式不应被视为影响对 CDASH 的符合性。

Implementers must determine what additional data fields to add to address study-specific and therapeutic area requirements, and applicable regulatory and business practices. Refer to CDASHIG Section 3.4 (How to Create New Data Collection Fields When No CDASHIG Field Has Been Defined) for more information on how to create data collection fields that have not already been described in this implementation guide.
实施者必须确定需要添加哪些额外的数据字段，以满足特定研究和治疗领域的要求，以及适用的监管和商业实践。有关如何创建在本实施指南中尚未描述的数据收集字段的更多信息，请参阅 CDASHIG 第 3.4 节（如何在未定义 CDASHIG 字段时创建新的数据收集字段）。

General Design Considerations for Completion Instructions
完工指令的一般设计考虑事项

Whenever possible, details related to the completion of a single field should be placed with the field itself on the CRF. If this is not possible due to the medium and/or system being used to create the CRFs, then it is permissible to include the field-level instructions at the top of the form, in what is generally considered the form-level instruction area. In some cases, such as when the form-level instructions are very lengthy or include graphics or flowcharts, a separate CRF completion instruction guideline may be required.
每当可能时，与单个字段完成相关的细节应与该字段本身放在 CRF 上。如果由于创建 CRF 所使用的媒介和/或系统无法做到这一点，则可以在表单顶部包含字段级说明，这通常被视为表单级说明区域。在某些情况下，例如当表单级说明非常冗长或包含图形或流程图时，可能需要单独的 CRF 完成说明指南。

General Content Considerations for Completion Instructions
完成说明的一般内容考虑事项

When creating form-level instructions for a CRF, the following points should be considered:
在为 CRF 创建表单级说明时，应考虑以下几点：

• The instructions should include clear references to the time period for which data are to be reported for the study, or to specific time windows that are allowed.
  说明应包括对研究中要报告数据的时间段或允许的特定时间窗口的明确参考。
• The instructions should provide references to protocol sections for the specifics of and/or limitations on the data to be reported.
  说明应提供对协议部分的参考，以便具体说明要报告的数据的细节和/或限制。
• The instructions should include any special instructions for additional reporting or actions required beyond what is collected on the CRF.
  说明应包括任何关于额外报告或在 CRF 上收集的内容之外所需采取的行动的特别说明。
• The instructions should include considerations on how data collected on one CRF might have an impact on data that are reported on a different CRF.
  说明应包括对在一个 CRF 上收集的数据如何影响在另一个 CRF 上报告的数据的考虑。
• The instructions should refer to any other forms that are related to the CRF being completed.
  说明应提及与正在填写的 CRF 相关的任何其他表格。

Should the sponsor choose, screen failure data are data collected for those who fail screening and who are not subsequently enrolled in the study. Section 10.1 of ICH E3 describes the reporting of subject disposition in the clinical study report. This section states that it may be "relevant to provide the number of patients screened for inclusion and a breakdown of the reasons for excluding patients during screening, if this could help clarify the appropriate patient population for eventual drug use." Although screen failure data may not be relevant for all studies, it is recommended that screen failure data be collected based on the needs of the protocol and drug development programs. Timely collection of screen failure data may also be used to identify eligibility criteria that contribute to enrollment challenges.
如果赞助方选择，筛选失败数据是指那些未能通过筛选且未随后入组研究的受试者所收集的数据。ICH E3 的第 10.1 节描述了临床研究报告中受试者处置的报告。这一节指出，提供筛选纳入患者的数量以及在筛选过程中排除患者的原因细分可能是“相关的，如果这有助于澄清最终药物使用的适当患者群体。”尽管筛选失败数据可能并不适用于所有研究，但建议根据方案和药物开发计划的需要收集筛选失败数据。及时收集筛选失败数据也可以用于识别导致入组挑战的资格标准。

Using CDASH, the minimum data to be collected should include a subject identifier and reason(s) for screen failure. Typically, there is a reason on the End of Study form indicating "Screen Failure". This information allows overall summarization of all subjects screened/enrolled and when captured, provides easy subject accountability for the Clinical Study Report. Other data may be considered for collection, such as date of informed consent, sex, race, date of birth or age, or other data to further describe the reason for ineligibility (e.g., the lab value that was out of range).
使用 CDASH，收集的最少数据应包括受试者标识符和筛选失败的原因。通常，在研究结束表格上会有一个指示“筛选失败”的原因。这些信息允许对所有筛选/入组的受试者进行总体汇总，并在捕获时为临床研究报告提供便捷的受试者责任追踪。还可以考虑收集其他数据，例如知情同意日期、性别、种族、出生日期或年龄，或其他数据以进一步描述不合格的原因（例如，超出范围的实验室值）。

SDTMIG does not provide a separate domain specifically for screen failure data and does not require that the screen failure data be included in SDTM. Data for screen failure subjects, if submitted, should be included in the appropriate SDTMIG domains. Refer to the SDTMIG for further guidance on submitting Screen Failure data.
SDTMIG 没有提供专门用于筛选失败数据的单独领域，也不要求将筛选失败数据包含在 SDTM 中。如果提交筛选失败受试者的数据，应将其包含在适当的 SDTMIG 领域中。有关提交筛选失败数据的进一步指导，请参阅 SDTMIG。

Data Collection to Facilitate Coding
数据收集以促进编码

Adverse Events, Medical History, and Prior and Concomitant Medications are often coded to standard dictionaries (thesauri). There are many coding dictionaries, but this section will focus on the Medical Dictionary for Regulatory Activities (MedDRA®) and the World Health Organization Drug Dictionary (WHO-DD) as examples, since these are common coding dictionaries.
不良事件、病史以及之前和同时使用的药物通常会被编码到标准词典（同义词库）。有许多编码词典，但本节将重点介绍医疗监管活动词典（MedDRA®）和世界卫生组织药物词典（WHO-DD）作为例子，因为这些是常见的编码词典。

The SDTMIG variable AEDECOD is the dictionary-derived text description of AETERM (the reported term for the adverse event) or AEMODIFY (the modified reported term). When coding with MedDRA®, the AEDECOD is the Preferred Term and is a required variable. Corresponding SDTMIG variables CMDECOD (for medications) and MHDECOD (for medical history items) are permissible SDTMIG variables. These are the equivalent of the preferred term in the dictionary used for coding, and when data are coded these SDTMIG variables should be provided.
SDTMIG 变量 AEDECOD 是从字典派生的 AETERM（不良事件的报告术语）或 AEMODIFY（修改后的报告术语）的文本描述。在使用 MedDRA®编码时，AEDECOD 是优选术语，并且是必需变量。相应的 SDTMIG 变量 CMDECOD（用于药物）和 MHDECOD（用于病史项目）是允许的 SDTMIG 变量。这些变量相当于用于编码的字典中的优选术语，当数据被编码时，这些 SDTMIG 变量应提供。

These --DECOD variables are not necessarily collected on CRFs. They are often determined from other collected variables (e.g., AETERM, CMTRT, and MHTERM). Conventions adopted in the collection of these reported terms can have an impact on the resulting --DECOD variables. If collected on a CRF, --DECOD values would be selected from sponsor-defined or CDISC controlled terminology.
这些 --DECOD 变量不一定在 CRF 上收集。它们通常是从其他收集的变量（例如 AETERM、CMTRT 和 MHTERM）中确定的。收集这些报告术语时采用的惯例可能会影响最终的 --DECOD 变量。如果在 CRF 上收集，--DECOD 值将从赞助商定义或 CDISC 控制的术语中选择。

CRF Designers should consult with medical coders, review relevant documentation, and ensure that all elements needed to facilitate the coding process are collected.
CRF 设计师应与医疗编码员咨询，审查相关文档，并确保收集所有促进编码过程所需的元素。

Coding Adverse Events and Medical History Items
编码不良事件和病史项目

Data managers are encouraged to enter into discussion with coding specialists and medical staff to develop guidance to sites in accordance with applicable coding conventions and other company/project agreements and requirements.
数据管理人员被鼓励与编码专家和医疗人员进行讨论，以根据适用的编码规范和其他公司/项目协议及要求，为各个站点制定指导方针。

Reported terms are often coded without other information for the subject. Therefore, sites should be advised that "nothing can be assumed", and that the reported term should include all information relevant to the event being reported. For example, if "Congestion" is reported as an adverse event for a particular subject, together with several other pulmonary events, the coder cannot assume that the congestion is "Lung congestion", rather than congestion of some other organ (e.g., nose, ear, etc.). The reported term "Congestion" will need to be queried before it can be coded.
报告的术语通常在没有其他信息的情况下进行编码。因此，应该告知各个站点“不能假设任何事情”，并且报告的术语应包括与所报告事件相关的所有信息。例如，如果“充血”被报告为某个特定受试者的不良事件，并且还有其他几个肺部事件，编码者不能假设充血是“肺充血”，而不是其他器官（例如，鼻子、耳朵等）的充血。报告的术语“充血”在编码之前需要进行查询。

Medications 药物

With regard to medications, the CDASH standard offers some guidance on the recording of medication names and on the use of additional Recommended/Conditional data collection fields (e.g., CMROUTE, CMINDC) to facilitate coding. See CDASHIG Section 8.1.1, Assumptions for Interventions Domains.
关于药物，CDASH 标准提供了一些关于记录药物名称的指导，以及使用额外的推荐/条件数据收集字段（例如，CMROUTE，CMINDC）以便于编码。请参见 CDASHIG 第 8.1.1 节，干预领域的假设。

The purpose of coding medications is usually to provide a "Standardized Medication Name" (CMDECOD) and a "Medication Class" (CMCLAS). Most dictionaries facilitate the derivation of the Standardized Medication Name on identification of the medication that was taken and the reason taken.
编码药物的目的是通常提供“标准化药物名称”（CMDECOD）和“药物类别”（CMCLAS）。大多数字典通过识别所服用的药物及其服用原因来帮助推导标准化药物名称。

It would be preferable to collect all active ingredients of a particular medication. In a clinical trial, however, this is impractical. There are numerous CRF design possibilities. When designing a collection tool, it is critical to ensure that the details appropriate to the trial and the sponsor's coding requirements are included. For example, betamethasone dipropionate is used topically; however, if the site records only betamethasone (which can be administered orally, as drops, or inhaled), the topical route of the drug will be lost. In this case, collecting route of administration (CMROUTE) or the indication (CMINDC) would provide the additional information needed to code this medication.
最好收集特定药物的所有活性成分。然而，在临床试验中，这并不实际。CRF 设计有许多可能性。在设计收集工具时，确保包含与试验和赞助商编码要求相关的细节至关重要。例如，倍氯米松二丙酸酯是用于局部的；然而，如果现场仅记录倍氯米松（可以口服、滴眼或吸入），则药物的局部给药途径将会丢失。在这种情况下，收集给药途径（CMROUTE）或适应症（CMINDC）将提供编码该药物所需的额外信息。

In summary, when medications are to be coded, the indication (CMINDC) and route (CMROUTE) or anatomical location (CMLOC) should be collected along with the medication name.
总之，在对药物进行编码时，应收集指示（CMINDC）和途径（CMROUTE）或解剖位置（CMLOC），以及药物名称。

The SDTMIG includes three types of special-purpose datasets:
SDTMIG 包括三种特殊用途的数据集：

• Domain datasets (Demographics (DM), Comments (CO), Subject Elements (SE), and Subject Visits (SV) which contain subject-level data.
  领域数据集（人口统计（DM）、评论（CO）、主题元素（SE）和主题访问（SV），其中包含主题级数据。
• Trial Design Model (TDM) datasets which contain trial-level data.
  试验设计模型（TDM）数据集，其中包含试验级数据。
• Relationship datasets 关系数据集

These datasets are described in SDTMIG Section 2.3. CDASH does not currently contain information on Trial Design Model, or Relationship datasets. CDASH standards are for collection of subject-level data, therefore the collection of Trial Design domains is out of the scope for CDASH. CDASHIG contains information on these Special-Purpose Domains: Demographics (DM), and Comments (CO).
这些数据集在 SDTMIG 第 2.3 节中进行了描述。CDASH 目前不包含试验设计模型或关系数据集的信息。CDASH 标准用于收集受试者级别的数据，因此试验设计领域的收集超出了 CDASH 的范围。CDASHIG 包含有关这些特殊用途领域的信息：人口统计（DM）和评论（CO）。

1. Each study must include the Demographics domain.
   每个研究必须包括人口统计学领域。
2. CDASH does not currently contain metadata information on SDTM Special-Purpose Domains (Subject Elements (SE) and Subjects Visits (SV)). The SDTM SE and SV domains are commonly derived/created during the SDTM dataset creation process. Each implementer has to determine the best practice within their organization for creating visits and collecting the information on any unplanned visits. See the SDTMIG Section 5 Subject Elements and Subject Visits for more information.
   CDASH 目前不包含关于 SDTM 特殊用途域（受试者元素（SE）和受试者访视（SV））的元数据。SDTM SE 和 SV 域通常是在 SDTM 数据集创建过程中派生/创建的。每个实施者必须在其组织内确定创建访视和收集任何未计划访视信息的最佳实践。有关更多信息，请参见 SDTMIG 第 5 节受试者元素和受试者访视。

Description/Overview for the CDASHIG CO - Comments Domain
CDASHIG CO - 评论领域的描述/概述

The CDASH IG Comments (CO) domain describes free text collected alongside other data on typical case report form (CRF) pages such as Adverse Events, when there is not a specified variable for the free text. The CDASHIG CO domain has no mandatory data elements for inclusion in a separate Comments CRF, and the recommendation is to avoid the creation of a General Comments CRF.
CDASH IG 评论 (CO) 领域描述了在典型的病例报告表 (CRF) 页面上收集的自由文本，这些页面包括不良事件，当没有为自由文本指定变量时。CDASHIG CO 领域没有强制性数据元素需要包含在单独的评论 CRF 中，建议避免创建一般评论 CRF。

Specification for the CDASHIG CO - Comments Domain
CDASHIG CO - 评论领域规范

Comments (CO) 评论 (CO)

Assumptions for the CDASHIG CO - Comments Domain
CDASHIG CO - 评论领域的假设

Solicited Comments versus Unsolicited Comments
征求意见与非征求意见

Solicited comments are defined as those comments entered in free-text data collection fields (such as "Please comment") that are intentionally included on the CRFs. These data collection fields provide the site with a pre-defined space to further explain or clarify an associated record within the CRF. For example, the Vital Signs CRF may include a solicited comment data collection field that enables recording of free text, such as "reason for performing assessment out of window".
征求意见被定义为在自由文本数据收集字段（例如“请评论”）中输入的评论，这些字段是故意包含在 CRF 中的。这些数据收集字段为现场提供了一个预定义的空间，以进一步解释或澄清 CRF 中的相关记录。例如，生命体征 CRF 可能包括一个征求意见的数据收集字段，允许记录自由文本，例如“在窗外进行评估的原因”。

Unsolicited comments are those comments entered outside of pre-defined data collection fields (also referred to as "marginal" comments as they are sometimes written in margins of paper CRFs). These may include marginal CRF comments written by site staff, notes written by the subject on paper diaries, or additional information collected through an eDC system function which collects comments that are not included as data collection fields on the eCRF. Although such comments may be intended to reduce queries, in practice they often lead to clinical data not being entered into the correct data collection field and may cause additional work in the data management process. The collection of unsolicited comments should be discouraged. If they are allowed, they should be reviewed and resolved during the conduct of the study.
未经请求的评论是指在预定义数据收集字段之外输入的评论（也称为“边际”评论，因为它们有时写在纸质 CRF 的边缘）。这些可能包括由现场工作人员撰写的边际 CRF 评论、受试者在纸质日记上写的笔记，或通过 eDC 系统功能收集的额外信息，这些信息并未包含在 eCRF 的数据收集字段中。尽管这些评论可能旨在减少查询，但实际上它们往往导致临床数据未输入到正确的数据收集字段中，并可能在数据管理过程中造成额外的工作。应当不鼓励收集未经请求的评论。如果允许收集，应在研究进行期间进行审查和解决。

Some unsolicited comments may be intended to avoid queries, for example "subject visit was delayed due to his holidays", and may not be regarded as clinical data. When these comments are permitted during data collection, the sponsor should have a process by which the comments are reviewed and processed. This should include a method to query and move relevant data to the appropriate form.
一些未经请求的评论可能旨在避免查询，例如“由于他的假期，主题访问被延迟”，并可能不被视为临床数据。当在数据收集期间允许这些评论时，赞助商应有一个审核和处理评论的流程。这应包括一种查询和将相关数据转移到适当表单的方法。

The Investigative site should be trained to enter clinical data in the appropriate data collection fields rather than making marginal notes on the CRF, and to use appropriate methods and tools to communicate to the monitor information that should not be included in the clinical data.
调查地点应接受培训，以在适当的数据收集字段中输入临床数据，而不是在 CRF 上做边注，并使用适当的方法和工具向监查员传达不应包含在临床数据中的信息。

Free Text versus Value List Fields
自由文本与值列表字段

Clinical data must be entered in appropriate data collection fields; otherwise, there is a potential for data that should be entered on other CRFs to be hidden within the comment. For example, if a general comment of "subject visit was delayed as he had the flu" was captured, this would necessitate that someone review the data and query the site to enter "flu" in an Adverse Event CRF and not leave it as a comment. An additional concern with free text comments is the potential for inappropriate, or sensitive, information to be included within general comments data collection fields. For example, a comment could contain a subject's name or may have unblinding information.
临床数据必须输入到适当的数据收集字段中；否则，可能会导致应在其他 CRF 上输入的数据隐藏在评论中。例如，如果记录了一条一般评论“受试者的访问因他得了流感而延迟”，这将需要有人审核数据并询问现场在不将其作为评论的情况下在不良事件 CRF 中输入“流感”。自由文本评论的另一个问题是可能在一般评论数据收集字段中包含不当或敏感信息。例如，评论可能包含受试者的姓名或可能有揭盲信息。

Free text comments are also inefficient for processing due to their variable and unstructured nature; they offer limited or no value for statistical analysis, as they cannot be tabulated.
自由文本评论由于其可变和非结构化的特性，在处理上也效率低下；它们对统计分析的价值有限或没有价值，因为无法进行表格化。

CRF development teams are encouraged to strive for data collection methods that maximize the use of pre-defined lists of responses rather than relying solely on free text comment fields. The recommendation is that CRF development teams consider what additional questions may be needed within a specific CRF, and what the typical responses would be. They can then create a standardized list of responses for those questions, and make the data collected more useful for analysis.
CRF 开发团队被鼓励努力采用数据收集方法，最大限度地利用预定义的响应列表，而不是仅仅依赖自由文本评论字段。建议 CRF 开发团队考虑在特定 CRF 中可能需要哪些额外问题，以及典型的响应是什么。然后，他们可以为这些问题创建一个标准化的响应列表，使收集的数据对分析更有用。

Considerations Regarding Usage of a General Comments CRF
关于使用一般评论 CRF 的考虑事项

Solicited comments often used to be collected on a General Comments CRF. In recent years though, most organizations have discontinued this practice.
征求的意见通常会在一般意见 CRF 上收集。然而近年来，大多数组织已停止这一做法。

The CDASHIG CO domain has no mandatory data elements and is not intended to encourage the creation of a General Comments CRF. The CDASHIG recommends against the use of a General Comments CRF. This recommendation is not meant to discourage investigators from providing unsolicited comments where they are appropriate, nor to discourage solicited free-text comment data collection fields that may appear within any CRF. Free text comment fields should be used to solicit comments where they are needed. When comments are collected, they should use a variable naming convention that is conformant to CDASH (e.g., COVAL may be used in any CRF because it is part of the SDTMIG specification).
CDASHIG CO 领域没有强制性数据元素，并不旨在鼓励创建一般评论 CRF。CDASHIG 不建议使用一般评论 CRF。此建议并不意味着要阻止研究人员在适当的情况下提供主动评论，也不阻止在任何 CRF 中出现的征求自由文本评论数据收集字段。自由文本评论字段应在需要时用于征求评论。当收集评论时，应使用符合 CDASH 的变量命名约定（例如，COVAL 可以在任何 CRF 中使用，因为它是 SDTMIG 规范的一部分）。

Example CRF for the CDASHIG CO - Comments Domain
示例 CRF 用于 CDASHIG CO - 评论领域

This CRF shows the use of a targeted comment to collect the reason a PK sample was drawn more than 5 minutes late.
此 CRF 显示了使用针对性评论来收集 PK 样本延迟超过 5 分钟的原因。

Example 1 示例 1

Example Data for the CDASHIG CO - Comments Domain
CDASHIG CO - 评论领域的示例数据

Examples are not available at this time.
目前没有可用的示例。

Description/Overview for the CDASHIG DM - Demographics Domain
CDASHIG DM - 人口统计领域的描述/概述

The Demographics (DM) CDASHIG domain includes essential data collection fields that describe each subject in a clinical study. The collection of some demographics data is useful to perform simple analyses based upon population stratification.
人口统计（DM）CDASHIG 领域包括描述临床研究中每个受试者的基本数据收集字段。收集一些人口统计数据对于基于人群分层进行简单分析是有用的。

Privacy concerns surrounding the DM & SC data were taken into account when these domains were created. For example, there are optional CDASHIG variables to collect the components of birthdate (e.g., BRTHDD, BRTHMO, and BRTHYY); therefore, limited elements of birthday may be collected and later mapped to the SDTMIG variable BRTHDTC. This approach provides flexibility in categorizing some variables to facilitate compliance with local privacy issues.
在创建这些领域时，考虑了与 DM 和 SC 数据相关的隐私问题。例如，有可选的 CDASHIG 变量用于收集出生日期的组成部分（例如，BRTHDD、BRTHMO 和 BRTHYY）；因此，可以收集有限的生日元素，并随后映射到 SDTMIG 变量 BRTHDTC。此方法在对某些变量进行分类时提供了灵活性，以便符合当地的隐私问题。

Collection of Age versus Date of Birth
年龄与出生日期的集合

It is recognized that sponsors may collect the Age or Date of Birth of the subject. In studies that are multi-regional, sponsors may need to enable the collection of either in order to be compliant to local regulations. But only one or the other should be collected for any given subject. When only AGE is collected, the sponsor is left with a window of uncertainty of, at most, 365 days. Knowing the precise date of birth provides the ability to calculate accurately an age for any date, however a precise (and complete) date of birth may be seen as "personally identifying information" for some privacy oversight boards or governmental regulators.
赞助商可能会收集受试者的年龄或出生日期是被认可的。在多地区的研究中，赞助商可能需要启用其中一种收集方式，以遵守当地法规。但对于任何特定受试者，只应收集其中一种。当仅收集年龄时，赞助商面临的最大不确定性为 365 天。知道确切的出生日期可以准确计算任何日期的年龄，然而，对于某些隐私监督机构或政府监管机构来说，确切（和完整）的出生日期可能被视为“个人识别信息”。

Collect the date of birth to the extent that the local regulatory authorities will allow.
收集出生日期，尽可能在当地监管机构允许的范围内。

• The best method is to collect a complete date of birth, and derive age.
  最佳方法是收集完整的出生日期，并推算年龄。
• When there are privacy concerns with collecting the complete date of birth, the recommendation is to collect year of birth at a minimum.
  当收集完整出生日期存在隐私问题时，建议至少收集出生年份。
• In cases when neither of the above can be implemented (e.g., cultural or regional considerations) then Age and Age Unit should be collected, and Date of Collection should be collected or derived from the Visit Date.
  在无法实施上述任何一种情况时（例如，文化或地区考虑），应收集年龄和年龄单位，并应收集或从访问日期推导出收集日期。
• Only use the AGETXT variable in very rare cases when only an age range or age description can be determined.
  仅在非常少见的情况下使用 AGETXT 变量，当只能确定年龄范围或年龄描述时。

Date of Birth should be implemented such that incomplete dates are enterable, as allowed by the data capture system.
出生日期应实施为可输入不完整日期，符合数据采集系统的要求。

See Section 3.6 Collection of Dates for more information.
请参阅第 3.6 节 日期收集以获取更多信息。

Collection of Sex 性收藏

The collection of some demographics data is useful to perform simple analyses based upon population stratification.
收集一些人口统计数据对于基于人口分层进行简单分析是有用的。

Collection of Ethnicity and Race
民族和种族的集合

Within the United States of America, collect Ethnicity before Race, per FDA requirement. A secondary analysis is often made using the phenotypic race of the subject. Collect race if required for the protocol and not prohibited by local laws and regulations.
在美国，根据 FDA 要求，先收集民族信息再收集种族信息。通常会使用受试者的表型种族进行二次分析。如果协议要求并且不违反当地法律法规，则收集种族信息。

In 2016, the U.S. Office of Management and Budget (OMB) issued its revised recommendations for the collection and use of race and ethnicity data by Federal agencies. FDA follows this directive and now recommends "the use of the standardized OMB race and ethnicity categories for data collection in clinical trials for two reasons. The use of the recommended OMB categories will help ensure consistency in demographic subset analyses across studies used to support certain marketing applications to FDA and across data collected by other government agencies".
在 2016 年，美国管理和预算办公室（OMB）发布了对联邦机构收集和使用种族及民族数据的修订建议。FDA 遵循这一指令，现在建议“在临床试验的数据收集中使用标准化的 OMB 种族和民族类别，原因有二。使用推荐的 OMB 类别将有助于确保在支持某些向 FDA 提交的市场申请的研究中，以及其他政府机构收集的数据中，人口子集分析的一致性。”

The Race values listed in the FDA Guidance are:
FDA 指导中列出的种族价值包括：

• American Indian or Alaska Native
  美洲印第安人或阿拉斯加原住民
• Asian 亚洲人
• Black or African American*
  黑人或非裔美国人*
• Native Hawaiian or Other Pacific Islander
  本土夏威夷人或其他太平洋岛民
• White 白色

*For studies where data are collected outside the U.S., the recommended categories are the same except for "Black" instead of "Black or African American".
对于在美国以外收集数据的研究，推荐的类别相同，只是将“黑人”替换为“黑人或非洲裔美国人”。

CDASH provides only one variable for Race. When the sponsor captures more than one race, the sponsors will need to create non-standard variables to store the collection of the multiple Races and map appropriately to the SDTMIG DM domain.
CDASH 仅提供一个种族变量。当赞助商捕获多个种族时，赞助商需要创建非标准变量来存储多个种族的集合，并适当地映射到 SDTMIG DM 领域。

Race Other has been included as a free-text field to capture responses. The use of this variable is optional and should be used with caution because, when submitting data to the FDA, the FDA requires that all races be mapped to the five standard races recognized by the FDA, and providing an Other, Specify field might lead to mapping errors or difficulties. RACE is R/C because some sponsors prefer to derive values that are compliant with the codelist RACE (e.g., as derived from values collected in CRACE).
种族“其他”已被纳入为自由文本字段以捕捉响应。使用此变量是可选的，应谨慎使用，因为在向 FDA 提交数据时，FDA 要求所有种族都必须映射到 FDA 认可的五个标准种族，提供“其他，具体说明”字段可能会导致映射错误或困难。种族是 R/C，因为一些赞助商更倾向于导出符合种族代码表的值（例如，从 CRACE 中收集的值导出）。

The category of ethnicity is similar to race but, as defined by the CDC, is an arbitrary classification based on cultural, religious, or linguistic traditions; ethnic traits, background, allegiance, or association. In a fairly heterogeneous country, such as in the U.S., ethnicity data might be useful only to confirm that ethnic groups are not being discriminated against by being unfairly excluded from clinical research. Other regulatory bodies may expect the reporting of ethnicity values (different than the U.S. FDA) which more appropriately reflect the population of their areas (e.g., Japanese for MHLW reporting to Japan). These may be collected using the CETHNIC variable with its corresponding codelist, ETHNICC.
民族类别与种族相似，但根据 CDC 的定义，它是一种基于文化、宗教或语言传统的任意分类；民族特征、背景、忠诚或关联。在一个相当异质的国家，如美国，民族数据可能仅用于确认民族群体没有因被不公平地排除在临床研究之外而受到歧视。其他监管机构可能会期望报告的民族值（与美国 FDA 不同）更适当地反映其地区的人口（例如，日本的 MHLW 报告中的日本人）。这些数据可以使用 CETHNIC 变量及其相应的代码表 ETHNICC 进行收集。

If more detailed information on race or ethnicity are required to further characterize the study subject, it is recommended that the presented choices be "collapsible" up to one of the five designations for race, as well as the two categories for representing ethnicity, as needed for reporting to FDA under its guidance. When these more detailed categorizations are desired, the use of race and ethnicity vocabulary tables located within Health Level Seven's Reference Information Model Structural Vocabulary Tables is recommended, as they are designed to collapse up in this manner. For the collection of this added detail or granularity, as the sponsor may require, CDASH provides the variables CRACE and CETHNIC, respectively.
如果需要更详细的种族或民族信息来进一步描述研究对象，建议所提供的选项可以“折叠”到五个种族类别中的一个，以及根据 FDA 指导报告所需的两个民族类别。当需要这些更详细的分类时，建议使用健康七级（Health Level Seven）参考信息模型结构词汇表中的种族和民族词汇表，因为它们被设计为以这种方式折叠。为了收集这些附加细节或粒度，赞助商可能需要，CDASH 分别提供变量 CRACE 和 CETHNIC。

Source: Collection of Race and Ethnicity Data in Clinical Trials; October 26, 2016.
来源：临床试验中的种族和民族数据收集；2016 年 10 月 26 日。

Collection of Special Optional Fields in Demographics
人口统计学中特殊可选字段的集合

The CDASHIG allows for collection of the Date of Informed Consent using the variable RFICDAT. If a sponsor chooses to collect Informed Consent using this variable, the data should not also be collected using DSSTDAT from the DS Domain. The data from RFICDAT would then be mapped to the SDTMIG variable DSSTDTC and the companion variables (e.g., DSTERM, DSDECOD) must be populated accordingly.
CDASHIG 允许使用变量 RFICDAT 收集知情同意日期。如果赞助商选择使用此变量收集知情同意，则不应同时使用 DS 领域中的 DSSTDAT 收集数据。RFICDAT 中的数据将映射到 SDTMIG 变量 DSSTDTC，并且相应的变量（例如 DSTERM、DSDECOD）必须相应填充。

The CDASH Model also defines a field for Death Date (DTHDAT) as a timing variable. It may be collected on any CRF deemed appropriate by the sponsor. The SDTMIG variables DTHDTC and DTHFL are mapped to the DM domain during the SDTM submission dataset creation process. The CDASH field Death Date may be mapped to other SDTMIG domains, as deemed appropriate by the sponsor (e.g., DS).
CDASH 模型还定义了一个死亡日期（DTHDAT）字段作为时间变量。它可以在赞助商认为合适的任何 CRF 上收集。在 SDTM 提交数据集创建过程中，SDTMIG 变量 DTHDTC 和 DTHFL 被映射到 DM 领域。CDASH 字段死亡日期可以根据赞助商的判断映射到其他 SDTMIG 领域（例如，DS）。

See Best Practice in Section 4.1.2 of the CDASHIG for additional guidance recommending that the same data not be collected more than one time per subject.
请参阅 CDASHIG 第 4.1.2 节中的最佳实践，以获取额外指导，建议同一数据不应对每个受试者收集超过一次。

Specification for the CDASHIG DM - Demographics Domain
CDASHIG DM - 人口统计领域规范

Demographics (DM) 人口统计 (DM)

Assumptions for the CDASHIG DM - Demographics Domain
CDASHIG DM - 人口统计领域的假设

The CDASHIG DM domain is a special-purpose domain that collects specific data elements that are mapped to the SDTMIG DM domain. Additional data elements that are not within the scope of the Demographics must be mapped to other domains.
CDASHIG DM 领域是一个特殊用途的领域，收集特定的数据元素，这些元素映射到 SDTMIG DM 领域。超出人口统计范围的其他数据元素必须映射到其他领域。

Example CRF for the CDASHIG DM - Demographics Domain
示例 CRF 用于 CDASHIG DM - 人口统计领域

Example 1 示例 1

Example 2 示例 2

Example Data for the CDASHIG DM - Demographics Domain
CDASHIG DM - 人口统计领域示例数据

Examples are not available at this time.
目前没有可用的示例。

This section reflects common practices implemented by a significant number of the organizations/companies that provided information/examples. Most subject-level data collected during a study are represented using one of the three SDTM general observation classes. Section 8.1 includes the CDASH Intervention domains, Section 8.2 includes the CDASH Events domains, and Section 8.3 includes the CDASH Findings Domains. Within each domain class, the domains are presented in alphabetical order. Readers should refer to Section 6 of the SDTMIG for additional information on these classes. Within each domain, a link is provided to the CDASHIG Domain Metadata table. The CDASHIG Domain Metadata tables include the variables that are commonly used by a significant number of the organizations/companies that provided information/examples. Implementers may add other variables from the CDASH model as needed. Other variables can be added if needed following the instructions in Section 3.4, How to Create New Data Collection Fields When No CDASHIG Field Has Been Defined.
本节反映了提供信息/示例的众多组织/公司的常见做法。在研究过程中收集的大多数主题级数据使用三种 SDTM 一般观察类别之一进行表示。第 8.1 节包括 CDASH 干预领域，第 8.2 节包括 CDASH 事件领域，第 8.3 节包括 CDASH 发现领域。在每个领域类别中，领域按字母顺序排列。读者应参考 SDTMIG 第 6 节以获取有关这些类别的更多信息。在每个领域中，提供了指向 CDASHIG 领域元数据表的链接。CDASHIG 领域元数据表包括由众多提供信息/示例的组织/公司常用的变量。实施者可以根据需要添加 CDASH 模型中的其他变量。如果需要，可以按照第 3.4 节的说明添加其他变量，即在未定义 CDASHIG 字段时如何创建新的数据收集字段。

The Interventions class includes CDASH domains that define collection standards for investigational treatments, therapeutic treatments, and procedures that are intentionally administered to the subject either as specified by the study protocol (e.g., exposure), coincident with the study assessment period (e.g., concomitant medications), or self-administered by the subject (such as alcohol, tobacco, or caffeine).
干预类包括 CDASH 领域，定义了对研究性治疗、治疗性治疗和程序的收集标准，这些治疗和程序是根据研究方案（例如，暴露）明确施加给受试者的，或与研究评估期同时发生（例如，同时用药），或由受试者自行施用（如酒精、烟草或咖啡因）。

1. CDASH --YN variables with the question text "Were there any interventions?" (e.g., "Were there any procedures?" or "Were there any concomitant medications?") are intended to assist in the cleaning of data and in confirming that there are no missing values. These variables are not included as part of the SDTM Intervention Domains for submission and are annotated as NOT SUBMITTED on the CRF.
   CDASH --YN 变量的问题文本为“是否有任何干预？”（例如，“是否有任何程序？”或“是否有任何伴随用药？”）旨在帮助清理数据并确认没有缺失值。这些变量不作为提交的 SDTM 干预领域的一部分，并在 CRF 上标注为未提交。
2. CDASH --CAT and/or -SCAT are generally not entered on the CRF by the sites. Implementers may pre-populate and display these category values to help the site understand what data should be recorded on the CRF. Implementers may also pre-populate hidden variables with the values assigned within their operational database. Categories and subcategories are determined per protocol design, and could be populated during the SDTM submission dataset creations.
   CDASH --CAT 和/或 -SCAT 通常不会由现场在 CRF 上输入。实施者可以预先填充并显示这些类别值，以帮助现场理解应在 CRF 上记录哪些数据。实施者还可以用其操作数据库中分配的值预先填充隐藏变量。类别和子类别根据协议设计确定，并可以在 SDTM 提交数据集创建期间填充。
3. Date and Time variables
   日期和时间变量
   1. CDASH date variables (e.g., --DAT, --STDAT, --ENDAT) are concatenated with the CDASH Time variables (e.g., --TIM, --STTIM, --ENTIM (if time is applicable) into the appropriate SDTM --DTC variables (e.g., --DTC, --STDTC, --ENDTC) using the ISO 8601 format.
      CDASH 日期变量（例如，--DAT，--STDAT，--ENDAT）与 CDASH 时间变量（例如，--TIM，--STTIM，--ENTIM（如果适用时间））连接成适当的 SDTM --DTC 变量（例如，--DTC，--STDTC，--ENDTC），使用 ISO 8601 格式。
   2. Collecting the time an intervention was started is only appropriate if it can be realistically determined and if there is a scientific reason for needing to know this level of detail. An example is where the subject is under the direct care of the site at the time the intervention was started, and the study design is such that it is important to know the intervention start time with respect to dosing.
      收集干预开始的时间只有在可以实际确定的情况下，并且有科学理由需要了解这一细节时才是合适的。一个例子是，当受试者在干预开始时处于研究地点的直接照护下，并且研究设计要求了解干预开始时间与给药之间的关系时。
4. CDASH variable -- REASND is used with SDTM variable --STAT only. The value "NOT DONE" in --STAT indicates that the subject was not questioned about the intervention or data was not collected. It does not mean that the subject had no interventions.
   CDASH 变量 -- REASND 仅与 SDTM 变量 --STAT 一起使用。--STAT 中的值 "NOT DONE" 表示受试者没有被询问关于干预的情况或数据未被收集。这并不意味着受试者没有接受干预。
5. Coding  编码
   1. When free text intervention treatments are recorded, the location may be included in the --TRT variable to facilitate coding (e.g., Liver Biopsy). Location is collected when the sponsor needs to identify the specific anatomical location of the intervention. This location information does not need to be removed from the verbatim --TRT when the SDTMIG submission datasets are created, but the --LOC variable will need to be populated with the anatomical location. Reference the SDTMIG for more information.
      当记录自由文本干预治疗时，位置可以包含在--TRT 变量中以便于编码（例如，肝活检）。当赞助方需要识别干预的特定解剖位置时，会收集位置。创建 SDTMIG 提交数据集时，这些位置信息不需要从逐字--TRT 中删除，但--LOC 变量需要填入解剖位置。有关更多信息，请参考 SDTMIG。
   2. --ATC1 through --ATC5, --ATC1CD through --ATC5CD. These Non-Standard (or SUPPQUAL) Variables are used only when the intervention is coded using the Anatomical Therapeutic Chemical Classification System. The numbers indicate the anatomical main group: "1" = the anatomical main group, "2" = the therapeutic main group, "3" = the therapeutic/pharmacological subgroup, "4" = chemical/therapeutic/pharmacological subgroup, "5" = chemical substance.
      --ATC1 到 --ATC5，--ATC1CD 到 --ATC5CD。这些非标准（或 SUPPQUAL）变量仅在使用解剖治疗化学分类系统编码干预时使用。数字表示解剖主要组：“1” = 解剖主要组，“2” = 治疗主要组，“3” = 治疗/药理亚组，“4” = 化学/治疗/药理亚组，“5” = 化学物质。
   3. The implementer may also add the MedDRA coding elements as Non-Standard Variables to the Intervention domain if this dictionary is used for coding.
      实施者还可以将 MedDRA 编码元素作为非标准变量添加到干预领域，如果使用该词典进行编码。
6. Location (--LOC) and related variables (--LAT, --DIR, -- PORTOT)
   位置 (--LOC) 和相关变量 (--LAT, --DIR, --PORTOT)
   1. Because the complete lists of controlled terminology for these variables may be too extensive to be relevant for a particular study CRF, sponsors may choose to include only subsets of the controlled terminology on the CRF.
      由于这些变量的受控术语完整列表可能过于庞大而与特定研究的 CRF 不相关，赞助商可以选择仅在 CRF 中包含受控术语的子集。
   2. --LOC could be a defaulted or hidden field on the CRF for pre-specified [--TRT]/Intervention Topic].
      --LOC 可以是 CRF 上的一个默认或隐藏字段，用于预先指定的 [--TRT]/干预主题。
7. Relative Timing Variables (See SDTMIG Section 4.1.4.7 for more information and details)
   相对时间变量（有关更多信息和细节，请参见 SDTMIG 第 4.1.4.7 节）
   1. For each study, the sponsor defines the study reference period in the DM domain using SDTMIG variables RFSTDTC and RFENDTC. Other sponsor-specified reference time points can be defined for other data collection situations. The CDASH variables --PRIOR and --ONGO may be collected in lieu of a "start date" or an "end date".
      对于每个研究，赞助商在 DM 领域使用 SDTMIG 变量 RFSTDTC 和 RFENDTC 定义研究参考期。对于其他数据收集情况，可以定义其他赞助商指定的参考时间点。CDASH 变量--PRIOR 和--ONGO 可以代替“开始日期”或“结束日期”进行收集。
   2. The CDASH variable --PRIOR is used to indicate if the --TRT (the topic item) started prior to either the study reference period or another sponsor-defined reference time point. When the study reference period is used as the anchor, --PRIOR may be used to derive a value (from the controlled terminology codelist STENRF) into the SDTM relative timing variable --STRF. When populating --STRF, if the value of --PRIOR is "Y", the value of "BEFORE" may be mapped to --STRF. The value in DM.RFSTDTC serves as the anchor for --STRF.
      CDASH 变量--PRIOR 用于指示--TRT（主题项目）是否在研究参考期或其他赞助商定义的参考时间点之前开始。当研究参考期作为锚点时，--PRIOR 可用于从受控术语代码表 STENRF 中推导出一个值到 SDTM 相对时间变量--STRF。在填充--STRF 时，如果--PRIOR 的值为“Y”，则“BEFORE”的值可以映射到--STRF。DM.RFSTDTC 中的值作为--STRF 的锚点。
      
      When a reference time point is used instead of the study reference period, --PRIOR may be used to derive a value into the SDTM relative timing variable --STRTPT. If the value of --PRIOR is "Y", the value of "BEFORE" may be derived into --STRTPT. Note: --STRTPT must refer to the "time point anchor" as described in --STTPT. The value in --STTPT can be either text (e.g., "VISIT 1") or a date (in ISO 8601 format).
      当使用参考时间点代替研究参考期时，可以使用--PRIOR 将值推导到 SDTM 相对时间变量--STRTPT。如果--PRIOR 的值为“Y”，则可以将“BEFORE”的值推导到--STRTPT。注意：--STRTPT 必须参考--STTPT 中描述的“时间点锚”。--STTPT 中的值可以是文本（例如，“VISIT 1”）或日期（采用 ISO 8601 格式）。
   3. The CDASH variable --ONGO is used to indicate if the value in --TRT is continuing beyond the study reference period or beyond another sponsor-defined reference time point. When the study reference period is used as the anchor, --ONGO may be used to derive a value into the SDTM relative timing variable --ENRF. If the value of --ONGO = "Y", the value of "AFTER" may be mapped to --ENRF.
      CDASH 变量--ONGO 用于指示--TRT 中的值是否在研究参考期或其他赞助商定义的参考时间点之后继续。当研究参考期作为锚点时，--ONGO 可用于推导 SDTM 相对时间变量--ENRF 的值。如果--ONGO 的值为"Y"，则"AFTER"的值可以映射到--ENRF。
      
      When a reference time point is used instead of the study reference period, --ONGO may be used to derive a value into the SDTM relative timing variable --ENRTPT. If the value of --ONGO is "Y", the value of "ONGOING" may be mapped to --ENRTPT. Note: --ENRTPT must refer to the "time point anchor" as described in --ENTPT. The value in --ENTPT can be either text (e.g., "TRIAL EXIT") or a date (in ISO 8601 format).
      当使用参考时间点代替研究参考期时，可以使用--ONGO 来推导 SDTM 相对时间变量--ENRTPT 的值。如果--ONGO 的值为“Y”，则“ONGOING”的值可以映射到--ENRTPT。注意：--ENRTPT 必须指向--ENTPT 中描述的“时间点锚”。--ENTPT 中的值可以是文本（例如，“试验退出”）或日期（采用 ISO 8601 格式）。

Description/Overview for the CDASHIG CM - Prior and Concomitant Medications Domain
CDASHIG CM - 先前和同时用药领域的描述/概述

The same basic data collection variables should be collected for all medications/treatments/therapies (Prior, General Concomitant Medications, and Medications of Interest). If additional fields are needed to collect other data about a medication of interest, those should be added as nonstandard fields. Note: Sponsor may use terms like "concomitant medications", "treatments", or "therapies" as appropriate for the study. The text below may use one of these terms, but sponsors can always use the term most appropriate for their study.
所有药物/治疗/疗法应收集相同的基本数据收集变量（先前用药、一般伴随用药和关注药物）。如果需要额外字段以收集有关关注药物的其他数据，则应将其作为非标准字段添加。注意：赞助商可以根据研究的需要使用“伴随用药”、“治疗”或“疗法”等术语。以下文本可能使用其中一个术语，但赞助商始终可以使用最适合其研究的术语。

The term "Prior" refers to medications/treatments that were started before study participation, since limited information may be available on prior medications taken by a subject; the core requirements were constrained to reflect this limitation.
“Prior”一词指的是在研究参与之前开始使用的药物/治疗，因为关于受试者之前所用药物的信息可能有限；核心要求受到限制以反映这一局限性。

Sponsors should define the appropriate collection period for prior and concomitant medications/treatments in the study protocol.
赞助商应在研究方案中定义先前和同时治疗/用药的适当收集周期。

Specification for the CDASHIG CM - Prior and Concomitant Medications Domain
CDASHIG CM - 先前和同时用药领域规范

Concomitant Medications (CM)
伴随用药 (CM)

Assumptions for the CDASHIG CM - Prior and Concomitant Medications Domain
CDASHIG CM - 先前和同时用药领域的假设

1. General medications/treatments are defined as any medications/treatments reported by a subject when asked if they have taken any medications in an open-ended way that does not ask about any specific drug. Additional information might be sourced by referring to a subject's medical record.
   一般药物/治疗被定义为在被问及是否服用过任何药物时，受试者以开放式方式报告的任何药物/治疗，而不询问任何特定药物。额外信息可能通过查阅受试者的病历获得。
2. Medications of interest are defined as any medications or classes of drugs specifically mentioned in the protocol and were not the primary focus for determining the CDASHIG Core designations for the domain (e.g., excluded medications, drugs requiring a washout period prior to dosing in study, or rescue medications).
   感兴趣的药物被定义为在方案中具体提到的任何药物或药物类别，并且不是确定该领域 CDASHIG 核心标识的主要焦点（例如，排除的药物、在研究中需要洗脱期的药物或救援药物）。
3. As with all the data collection variables recommended in the CDASH standard, it is assumed that sponsors will add other data variables as needed to meet protocol-specific and other data collection requirements (e.g., TA-specific data elements and others as required per protocol, business practice and operating procedures).
   根据 CDASH 标准推荐的所有数据收集变量，假设赞助商会根据需要添加其他数据变量，以满足特定于方案的和其他数据收集要求（例如，特定于治疗领域的数据元素以及根据方案、业务实践和操作程序所需的其他数据）。
4. The CMOCCUR field provides a structure for capturing the occurrence of specific medications of interest.
   CMOCCUR 字段提供了一个结构，用于捕捉特定感兴趣药物的发生情况。
5. If sponsors wish to capture non-pharmacological therapies (e.g., Surgery procedures, aromatherapy, massage, acupuncture), they can use the PR domain.
   如果赞助商希望捕捉非药物疗法（例如，手术程序、芳香疗法、按摩、针灸），他们可以使用 PR 领域。

Example CRF for the CDASHIG CM - Prior and Concomitant Medications Domain
示例 CRF 用于 CDASHIG CM - 先前和同时用药领域

Example 1 示例 1

Example Data for the CDASHIG CM - Prior and Concomitant Medications Domain
CDASHIG CM - 先前和同时用药领域的示例数据

Examples are not available at this time.
目前没有可用的示例。

Description/Overview for the CDASHIG EC - Exposure as Collected and the CDASHIG EX - Exposure Domains
CDASHIG EC - 收集的暴露描述/概述和 CDASHIG EX - 暴露领域

In the SDTMIG, the Exposure (EX) domain is used to represent exposure to study treatment as described in the protocol. The Exposure as Collected (EC) domain is used to represent the data as collected on the CRF. The CDASHIG EC domain is used in a study when the SDTMIG EX domain cannot be directly populated with the data collected on the CRF.
在 SDTMIG 中，暴露（EX）领域用于表示根据方案描述的研究治疗暴露。收集的暴露（EC）领域用于表示在 CRF 上收集的数据。当 SDTMIG EX 领域无法直接用 CRF 上收集的数据填充时，CDASHIG EC 领域将在研究中使用。

CDASHIG EC is used when:
CDASHIG EC 在以下情况下使用：

1. An alias for the actual treatment name is used (e.g., the study is masked) rather than the actual treatment name (e.g., the study is open label).
   用于实际治疗名称的别名（例如，研究是盲法）而不是实际治疗名称（例如，研究是开放标签）。
2. Exposure data are collected in non-protocol-specified units (e.g., tablets).
   暴露数据以非协议指定的单位收集（例如，药片）。
3. Scheduled and/or missed doses are collected.
   计划和/或漏服的剂量被收集。
4. Planned doses (e.g., a calculation based on body weight) are collected in addition to actual doses given.
   计划剂量（例如，基于体重的计算）除了实际给药剂量外，还会被收集。

A sponsor may choose to always collect exposure data using the CDASHIG EC domain.
赞助商可以选择始终使用 CDASHIG EC 域收集曝光数据。

Extensive discussion of the use of the EC and EX domains, including examples of data collection, is available in the SDTMIG.
关于 EC 和 EX 领域使用的广泛讨论，包括数据收集的示例，详见 SDTMIG。

Specification for the CDASHIG EC - Exposure as Collected and the EX - Exposure Domains
CDASHIG EC - 收集的暴露规范和 EX - 暴露领域

Exposure as Collected (EC)
收集的曝光 (EC)

Exposure (EX) 曝光 (EX)

1. If the SDTMIG EC dataset would be an exact duplicate of the SDTMIG EX dataset, then the sponsor may choose to collect data using either the CDASHIG EC or EX domain. (See the SDTMIG for additional information on submission.)
   如果 SDTMIG EC 数据集与 SDTMIG EX 数据集完全相同，则赞助商可以选择使用 CDASHIG EC 或 EX 领域收集数据。（有关提交的更多信息，请参见 SDTMIG。）
2. The collected --TRT value is the name of the study treatment that is known to the subject or investigative site (e.g., ECTRT = "TABLET A" when EXTRT= <treatment name>).
   收集的 --TRT 值是受试者或研究地点已知的研究治疗名称（例如，当 EXTRT = <治疗名称> 时，ECTRT = "TABLET A"）。

3. If dosing data are collected in non-protocol-specified units, the data are collected in CDASHIG EC dataset, then programmatically converted to the protocol-specified units when the data are mapped to the SDTMIG EX domain.
   如果在非协议指定单位中收集剂量数据，这些数据将被收集在 CDASHIG EC 数据集中，然后在数据映射到 SDTMIG EX 领域时，程序性地转换为协议指定单位。

   Dosing units specified in the protocol 方案中规定的给药单位	Dosing information as collected 剂量信息已收集 on the CRF and represented in EC 在 CRF 上并表示在 EC 中	Representation in EX 在 EX 中的表现
   200 mg tablet 200 毫克片剂	2 tablets 2 片	400 mg 400 毫克
   100 mg capsule 100 毫克胶囊	1 capsule 1 粒胶囊	100 mg 100 毫克
   5 mg/kg 5 毫克/千克	99 mL 99 毫升	5 mg/kg 5 毫克/千克

4. If a treatment is such that start and stop times are not required, and only one dosing date is collected, then the collected dosing date will map to both the start date (--STDTC) and end date (--ENDTC) in the submitted exposure dataset(s).
   如果治疗不需要开始和结束时间，并且只收集一个给药日期，则收集的给药日期将映射到提交的暴露数据集中开始日期（--STDTC）和结束日期（--ENDTC）。
5. If scheduled dosing is collected, the ECMOOD variable may be used to distinguish between "SCHEDULED" and "PERFORMED" dosing records. The sponsor may choose to use this variable to capture multiple scheduled dosing records, if needed.
   如果收集了计划给药，ECMOOD 变量可用于区分“计划”和“执行”的给药记录。赞助商可以选择使用此变量来捕获多个计划给药记录（如有需要）。
6. ECOCCUR:
   1. ECOCCUR value of "N" indicates a dose was not taken, not given, or missed.
      ECOCCUR 值的"N"表示未服用、未给予或漏服的剂量。
   2. ECOCCUR is generally not applicable for Scheduled records.
      ECOCCUR 通常不适用于计划记录。
   3. ECOCCUR = "N" is the standard representation of the collected doses not taken, not given, or missed.
      ECOCCUR = "N" 是未服用、未给予或漏服的收集剂量的标准表示。
7. Dose amount variables (e.g., ECDOSE, ECDOSTXT) must not be set to zero (0) as an alternative method for indicating doses not taken, not given, or missed.
   剂量金额变量（例如，ECDOSE，ECDOSTXT）不得设置为零（0），作为指示未服用、未给药或漏服剂量的替代方法。

Example CRFs for the CDASHIG EC- Exposure as Collected and the CDASHIG EX - Exposure Domains
CDASHIG EC-暴露收集示例 CRF 和 CDASHIG EX-暴露领域

Example 1 示例 1

Example 2 示例 2

Example 3 示例 3

Example Data for the CDASHIG EC - Exposure as Collected Domain
CDASHIG EC - 收集的领域中的暴露示例数据

Examples are not available at this time.
目前没有可用的示例。